2025 17 3 0 105

Subcutaneous Hematoma as an Unusual Presentation of Chronic Myelogenous Leukemia following Bone Marrow Aspiration: A Case Report and Narrative Review 2 2 Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm characterized by the presence of the BCR-ABL1 fusion gene, also known as the Philadelphia chromosome. Bleeding complications are uncommon in the chronic phase of CML due to preserved platelet function. However, rare cases of subcutaneous hematoma have been reported in association with factor XIII deficiency or other coagulopathies. We report the case of a 19-year-old adolescent diagnosed with CML who developed a subcutaneous hematoma after bone marrow aspiration. The patient presented with localized swelling and tenderness at the aspiration site, which was later confirmed as a hematoma on imaging. Laboratory tests revealed a preserved platelet count, but suggested a possible underlying coagulopathy. Further investigation revealed a factor XIII deficiency contributing to the unusual presentation. This case highlights the importance of considering rare bleeding disorders, such as factor XIII deficiency, in patients with CML who present with unusual bleeding manifestations. Early recognition and management of such complications are critical for optimal patient outcomes. 1 4 2025/07/4 1404/4/13 2025/09/24 1404/7/2 Pourya Mashategan Pourya Mashategan Department of Pediatrics, School of Medicine, Baqiyatallah University of Medical Sciences, Tehran, Iran. Hassan Abolghasemi Hassan Abolghasemi Department of Pediatrics, School of Medicine, Baqiyatallah University of Medical Sciences, Tehran, Iran. HassanAbol@Yahoo.com Mohammad Kazem Emami Meibodi Mohammad Kazem Emami Meibodi Department of Orthopedics, School of Medicine, Baqiyatallah University of Medical Sciences, Tehran, Iran. dr.mkemamimeybodi@gmail.com Chronic myeloid leukemia Subcutaneous hematoma Bleeding complications Factor XIII deficiency BCR-ABL fusion gene Bone marrow aspiration Abdullah IA, Ghada SA, Arwa ZA. Unilateral Subhyaloid Hemorrhage as a Presenting Sign of Chronic Myeloid Leukemia. American Journal of Case Reports. 2022.##Shady Adnan A, Shady Adnan A, Shady A-A, Daehong K, Daehong K, Helena H, et al. Characterization of p190-Bcr-Abl chronic myeloid leukemia reveals specific signaling pathways and therapeutic targets. Leukemia. 2020.##Zehtabcheh S, Yousefi AM, Salari S, Safa M, Momeny M, Ghaffari SH, et al. Abrogation of histone deacetylases (HDACs) decreases survival of chronic myeloid leukemia cells: New insight into attenuating effects of the PI3K/c‐Myc axis on panobinostat cytotoxicity. Cell Biology International. 2021;45(5):1111-21.##Htet Lin H, Htet Lin H, Weixiang L, Weixiang L, Joshua W, Joshua W, et al. Classic myeloproliferative neoplasms in Singapore: A population-based study on incidence, trends, and survival from 1968 to 2017. Cancer Epidemiology. 2022.##Ashraf A, Ashraf A, Sara S, Sara S, Dina Sameh S, Dina Sameh S, et al. Hematoma or Bleeding As Initial Presentation of Chronic Myeloid Leukemia (CML): Review. Blood. 2022.##David KI, Farshid D, Farshid D, Sarah Schellhorn M, Sarah Schellhorn M, Sarah Schellhorn M, et al. Prediction model for mortality after intracranial hemorrhage in patients with leukemia. American Journal of Hematology. 2011.##Höglund M, Sandin F, Simonsson B. Epidemiology of chronic myeloid leukaemia: an update. Ann Hematol. 2015;94 Suppl 2:S241-7.##Verena SH, Verena SH, Michele B, Michele B, Joerg H, Joerg H, et al. The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries. Leukemia. 2015.##Yiming C, Yiming C, Haijun W, Haijun W, Hagop MK, Hagop MK, et al. Trends in chronic myeloid leukemia incidence and survival in the United States from 1975 to 2009. Leukemia & Lymphoma. 2013.##Manoj L, Manoj L, Hans Raj P, Hans Raj P, Gopal Raj P, Gopal Raj P, et al. Spontaneous Soft Tissue Haematomas- A Rare Presentation of Chronic Myeloid Leukemic (CML). Journal of clinical and diagnostic research : JCDR. 2015.##Louise K, Louise K, Kate B, Kate B, Gaurav S, Gaurav S, et al. Gastrointestinal bleeding in a chronic myeloid leukaemia patient precipitated by dasatinib-induced platelet dysfunction: Case report. Platelets. 2015.##Vaibhav Raj G, Vaibhav Raj G, Akash S, Akash S, Neha Y, Neha Y, et al. Spontaneous scapular region hematoma extending upto anterior chest wall in a patient of chronic myeloid leukaemia: an unusual site presentation. International Surgery Journal. 2022.##Rebecca KJ, Rebecca K-J, Tammuella S, Tammuella S, Cindy L, Cindy AL. Identification and Basic Management of Bleeding Disorders in Adults. Journal of the American Board of Family Medicine. 2014.##Yanzhi W, Yanzhi W, Lina W, Lina W, Yaming X, Ya-Ming X, et al. Bleeding with negative coagulation screening test as initial presentation of chronic myelogenous leukemia managed by fresh frozen plasma: A case report. Medicine. 2019.##Ankur J, Ankur J. A rare case of chronic myeloid leukemia with acquired von Willebrand disease presenting as subdural hematoma. Journal of Cancer Research and Therapeutics. 2015.##Farjah HA, Leena A, Ghada E, Aamer A, Fatmah SA. Bleeding Diathesis as the Initial Presentation of Chronic Myeloid Leukemia: A Case Series. Cureus. 2023.## ##

Detection of T315I Mutation in Ph+ Leukemias: Clinical Insights from One Case Report 2 2 The reciprocal translocation between chromosomes 9 and 22, known as the Philadelphia chromosome, results in the formation of the BCR/ABL fusion gene. This genetic aberration leads to dysregulation of intracellular kinase activity. The detection of the Philadelphia chromosome is a critical component of the diagnostic evaluation of myeloproliferative neoplasms and acute lymphoid leukemia. In treatments involving tyrosine kinase inhibitors, at least 70 genetic variants have been documented as factors that induce resistance to drugs. This includes the T315I mutation, which has been identified as the most prevalent in multiple countries and is of significant clinical significance. This mutation is detected in patients who have experienced therapeutic failure, thereby significantly restricting the available treatment options. In Colombia, the prevalence of this mutation and the dynamics of its appearance are not yet fully understood. Furthermore, there is a paucity of information regarding the management and prognosis of patients who express the mutation. In this study, the genomic DNA of 26 patients with Philadelphia chromosome was analyzed using the real-time molecular technique PCR. The objective was to identify the T315I genetic variant, which was positive in two of the patients diagnosed with CML. We present a case of a 39-year-old female patient diagnosed with Ph+ CML who exhibited resistance to treatment and detection of this mutation. 5 13 2025/07/42025/07/14 1404/4/23 2025/09/242025/09/11 1404/6/20 Carolina Jaramillo Jaramillo Carolina Jaramillo Jaramillo School of Bacteriology, Colegio Mayor de Antioquia, Colombia. Juliana Pérez Mejía Juliana Pérez Mejía Health Sciences, Colegio Mayor de Antioquia, Colombia. Sara María Rave Zapata Sara María Rave Zapata Antioquia, Colegio Mayor de Antioquia, Colombia. Maria Isabel Villa Palacio Maria Isabel Villa Palacio Faculty of Health Sciences, Colegio Mayor de Antioquia, Colombia. Diana Carolina Velasco Cardona Diana Carolina Velasco Cardona Health Sciences, Colegio Mayor de Antioquia, Colombia. dcvelasco@est.colmayor.edu.co Chronic myeloproliferative neoplasm Philadelphia chromosome BCR/ABL. Lim MS, Leval L, Quintanilla-Martinez L. Commentary on The 2008 WHO classification of mature T- and NK-cell neoplasms. J Hematop. 2009;2(2).##Lloyd R V. Hematopathology. In: Pathology: Historical and Contemporary Aspects. Cham: Springer; 2023.##Zhang L, Liu Y, Wang L, Wang L, Zheng L, He W, et al. A novel research model of clonal evolution in mantle cell lymphoma at the single-cell genomic level. Genes Dis. 2025;12(3):101406.##Moura MC, Davalos V, Planas-Serra L, Alvarez-Errico D, Arribas C, Ruiz M, et al. Epigenome-wide association study of COVID-19 severity with respiratory failure. EBioMedicine. 2021;66.##Pérez Mejía J, Acevedo Toro P. Epigenética: una nueva herramienta para el estudio de la leucemia mieloide crónica TT - Epigenetics: a new tool for the study of chronic myeloid leukemia. 2013.##Aspa-Cilleruelo JM, de Hontanar Torres GL, Gómez MM, Mazo EM. Neoplasias mieloproliferativas crónicas. Clasificación. Leucemia mieloide crónica. Medicine - Programa de Formación Médica Continuada Acreditado. 2024 Nov;14(20):1149-56.##Roychowdhury S, Talpaz M. Managing resistance in chronic myeloid leukemia. Blood Rev. 2011;25(6).##Minciacchi VR, Kumar R, Krause DS. Chronic myeloid leukemia: a model disease of the past, present and future. Cells. 2021;10(1):117.##Nguyen T, Harama D, Tamai M, Kagami K, Komatsu C, Kasai S, et al. Synergistic effect of asciminib with reduced doses of ponatinib in human Ph+ myeloid leukemia with the T315M mutation. Int J Hematol. 2025;1-11.##Lavallade King's College London H. Chronic myeloid leukaemia. Medicine. 2013 May;##Morales C, Cárdenas V, Valencia JE, Ribón G, Manrique R. Leucemia mieloide crónica: diagnóstico y tratamiento TT - Chronic myeloid leukemia: diagnosis and treatment. CES Medicina. 2010;24(1).##Zhang Y, Rowley JD. Chronic myeloid leukemia: Current perspectives. 2011.##Valencia-Serna J, Gul-Uludaǧ H, Mahdipoor P, Jiang X, Uludaǧ H. Investigating siRNA delivery to chronic myeloid leukemia K562 cells with lipophilic polymers for therapeutic BCR-ABL down-regulation. Journal of Controlled Release. 2013;172(2).##Liu-Dumlao T, Kantarjian H, Thomas DA, O'Brien S, Ravandi F. Philadelphia-positive acute lymphoblastic leukemia: Current treatment options. Curr Oncol Rep. 2012;14(5).##Enrico A, Leukemia MJAL. Philadelphia Positive (Ph1) (Incidence Classifications, Prognostic Factor in ALL Principles of ALL Therapy. In: Clinical Epidemiology of Acute Lymphoblastic Leukemia - From the Molecules to the Clinic. 2013.##Adesanya AE. Characterization of T315I BCR-ABL1-mediated drug resistance in chronic myeloid leukemia: new regulatory mechanism and clinical detection assay. 2024.##Shafi O, Rajpar R, Kanwal F, Waqas M, Khan OJ, Raveena, et al. Leukemogenesis in Acute Lymphoblastic Leukemia through the Lens of Developmental Dynamics of Lymphoid Progenitor Cells: a systematic review [Internet]. 2024. Available from:##Baer C, Meggendorfer M, Haferlach C, Kern W, Haferlach T. Detection of ABL1 kinase domain mutations in therapy-naïve BCR-ABL1-positive acute lymphoblastic leukemia. Haematologica. 2021;107(2):562.##Rowley JD. A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature. 1973;243(5405).##Cortes J, Kantarjian H. Advanced-phase chronic myeloid leukemia. 2003.##Al-Ali HK, Heinrich MC, Lange T, Krahl R, Mueller M, Müller C. High incidence of BCR-ABL kinase domain mutations and absence of mutations of the PDGFR and KIT activation loops in CML patients with secondary resistance to imatinib. Hematology Journal. 2004;5(1).##Kantarjian H, Giles F, Wunderle L, Bhalla K, O'Brien S, Wassmann B. Nilotinib in Imatinib-Resistant CML and Philadelphia Chromosome-Positive ALL. New England Journal of Medicine. 2006;354(24).##Roche-Lestienne C, Soenen-Cornu V, Grardel-Duflos N, Laï JL, Philippe N, Facon T. Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood. 2002;100(3).##BJ RDR, CL HSA, HK AA, DJ ERE, SF OERE, JM OFO. Activity of a Specific Inhibitor of the Bcr-Abl Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia With the Philadelphia Chromosome. N Engl J Med. 1038;344(14).##O'Dwyer ME, Mauro MJ, Kurilik G, Mori M, Balleisen S, Olson S. The impact of clonal evolution on response to imatinib mesylate (STI571) in accelerated phase CML. Blood. 2002;100(5).##Cervantes F, Hernández-Boluda JC, Steegmann JL, Conde E, Alvarez-Larrán A, López-Jiménez J. Imatinib mesylate therapy of chronic phase chronic myeloid leukemia resistant or intolerant to interferon: Results and prognostic factors for response and progression-free survival in 150 patients. Haematologica. 2003;88(10).##Mian AA, Haberbosch I, Khamaisie H, Agbarya A, Pietsch L, Eshel E, et al. Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1T315I and BCR-ABL1T315I-E255K. Ann Hematol. 2021;100(8):2023-9.##Navath S, Navath PA. Advances in the Treatment of Ph+ Chronic Myeloid Leukemia: A Comprehensive Study. International Journal of Cancer Therapeutics. 2024;1(1):37-41.##https://doi.org/10.55124/jct.v1i1.235##Miething C, Feihl S, Mugler C, Grundler R, Bubnoff N, Lordick F. The Bcr-Abl mutations T315I and Y253H do not confer a growth advantage in the absence of imatinib. Leukemia. 2006;20(4).##Liu J, Zhang Y, Huang H, Lei X, Tang G, Cao X, et al. Recent advances in Bcr‐Abl tyrosine kinase inhibitors for overriding T315I mutation. Chem Biol Drug Des. 2021;97(3):649-64.##Breccia M, Abruzzese E, Castagnetti F, Bonifacio M, Gangemi D, Sorà F, et al. Ponatinib as second-line treatment in chronic phase chronic myeloid leukemia patients in real-life practice. Ann Hematol. 2018 Sep 19;97(9):1577-80.##Polo VA, Sossa C, Boquimpani C, Salazar LA, Munevar I, Gómez R, et al. Real World Evidence From 2 Decades of First-Line TKI Therapy in Chronic Myeloid Leukemia (CML): Insights From ACHO's RENEHOC Registry. Clin Lymphoma Myeloma Leuk. 2025;25(5):290- 301.##Vásquez Palacio G, Ramírez GC, Muskus CE, Torres JD, Aya CA. Detección de mutaciones en el dominio tirosina quinasa de BCR-ABL1 en pacientes colombianos con leucemia mieloide crónica LMC, resistentes al imatinib. Revista Colombiana de Cancerología. 2018 Jan;22(1):8-17.##Yolima Méndez-Camacho, Mónica Giraldo-Castaño, María Fernanda Rocha. Identification of emotional and social needs and access to health services of patients diagnosed with Chronic Myeloid Leukemia in Colombia. RevColHematolOncol. 2021;8(1):10-7.##Osman AEG, Deininger MW. Chronic Myeloid Leukemia: Modern therapies, current challenges and future directions. Blood Rev. 2021;49.##Tadesse F, Asres G, Abubeker A, Gebremedhin A, Radich J. Spectrum of BCR-ABL Mutations and Treatment Outcomes in Ethiopian Imatinib-Resistant Patients With Chronic Myeloid Leukemia. JCO Glob Oncol. 2021;##Bahram C, Zaker F, Mousavi SA, Kazemi A, Ostadali M, Nadali F. Evaluation of T315I mutation frequency in chronic myeloid leukemia patients after imatinib resistance. Hematology. 2013;18(3).##Shih LY, Kuo MC, Kuo CY, Lin TH, Bai LY, Chen TY. Emerging kinetics of BCR-ABL1 mutations and their effect on disease outcomes in chronic myeloid leukemia patients with imatinib failure. Leuk Res. 2013;37(1).##Li B, Brady SW, Ma X, Shen S, Zhang Y, Li Y. Therapy-induced mutations drive the genomic landscape of relapsed acute lymphoblastic leukemia. Blood. 2020;135(1).##Khorashad JS, Kelley TW, Szankasi P, Mason CC, Soverini S, Adrian LT. BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: Frequency and clonal relationships. Blood. 2013;121(3).##Izzo B, Gottardi EM, Errichiello S, Daraio F, Baratè C, Galimberti S. Monitoring Chronic Myeloid Leukemia: How Molecular Tools May Drive Therapeutic Approaches. 2019.##Hughes T, Deininger M, Hochhaus A, Branford S, Radich J, Kaeda J. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: Review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. 2006.##Liu J, Yang H, Xu X, Yi S, Meng L. Mutations in the bcr-abl1 kinase domain in patients with chronic myeloid leukaemia treated with tkis or at diagnosis. Oncol Lett. 2020;20(2).##Khair HE, Mohamed BA, Nour BY, Waggiallah HA. Prevalence of BCR-ABL T315I Mutation in Different Chronic Myeloid Leukemia patients Categories. Pakistan Journal of Biological Sciences. 2022;25(2).##Kim WS, Kim D, Kim DW, Kweon IY, Kim SH, Goh HG. Dynamic change of T315I BCR-ABL kinase domain mutation in Korean chronic myeloid leukaemia patients during treatment with Abl tyrosine kinase inhibitors. Hematol Oncol. 2010;28(2).## ##

Comparison of Cytochemistry and Flow Cytometry for Leukemia Immunophenotyping: A Systematic Review and Meta-Analysis 2 2 Background: Accurate diagnosis and classification of leukemia are essential for effective treatment planning. Traditional cytochemistry relies on enzyme-based staining for morphological evaluation, while flow cytometry (FCM) employs monoclonal antibodies to detect multiple surface and intracellular markers. This systematic review and meta-analysis compared the diagnostic accuracy of cytochemistry and FCM in leukemia immunophenotyping. Methods: A systematic search of PubMed and Google Scholar was conducted according to PRISMA guidelines. Studies evaluating sensitivity, specificity, and accuracy of cytochemistry and FCM in diagnosing acute and chronic leukemia were included. Data extraction covered study characteristics, diagnostic markers, and performance outcomes. Meta-analysis was performed to compare diagnostic values across methods. Results: Eleven eligible studies comprising pediatric and adult leukemia cases were analyzed. Cytochemical stains such as Myeloperoxidase (MPO) and Sudan Black B (SBB) showed high specificity (91–100%) and moderate-to-high sensitivity (60–97%), while Periodic Acid–Schiff (PAS) and Nonspecific Esterase (NSE) had lower reliability. FCM demonstrated superior diagnostic performance with average sensitivity of 87.7% and specificity of 85.6%, achieving >95% accuracy in several studies. Marker panels including CD3, CD45, CD79a, and MPO enabled precise subtype differentiation and minimal residual disease (MRD) detection. Conclusion: Cytochemistry remains useful as an affordable screening tool in resource-limited settings, but FCM provides greater sensitivity, specificity, and comprehensive immunophenotypic data, making it the preferred method for leukemia diagnosis and monitoring. Combining both approaches can enhance diagnostic performance across diverse clinical contexts. 14 25 2025/07/42025/07/142025/08/19 1404/5/28 2025/09/242025/09/112025/09/11 1404/6/20 Ajay Kumar Ajay Kumar Department of General Medicine, Teerthanker Mahaveer Medical College & Research Centre,Teerthanker Mahaveer University, Moradabad, UP, India. drajaykumar30july@gmail.com Prithpal Singh Matreja Prithpal Singh Matreja Department of Pharmacy, Teerthanker Mahaveer Medical College & Research Centre, Teerthanker Mahaveer University, Moradabad, UP, India. Vinod Kumar Singh Vinod Kumar Singh Department of General Medicine, Teerthanker Mahaveer Medical College & Research Centre,Teerthanker Mahaveer University, Moradabad, UP, India. Seema Awasthi Seema Awasthi Department of Pathology, Teerthanker Mahaveer Medical College & Research Centre,Teerthanker Mahaveer University, Moradabad, UP, India. Leukemia Cytochemistry Flow Cytometry Immunophenotyping Epstein, F. H.; Cline, M. J. The Molecular Basis of Leukemia. N Engl J Med 1994, 330 (5), 328-336. ##https://doi.org/10.1056/NEJM199402033300507##Kampen, K. R. The Discovery and Early Understanding of Leukemia. Leukemia Research 2012, 36 (1), 6-13. ##https://doi.org/10.1016/j.leukres.2011.09.028##Tebbi, C. K. Etiology of Acute Leukemia: A Review. Cancers 2021, 13 (9), 2256. ##https://doi.org/10.3390/cancers13092256##Gralnick, H. R.; Galton, D. A. G.; Catovsky, D.; Sultan, C.; Bennett, J. M. Classification of Acute Leukemia. Ann Intern Med 1977, 87 (6), 740-753. ##https://doi.org/10.7326/0003-4819-87-6-740##Schumacher, H. R.; Alvares, C. J.; Blough, R. I.; Mazzella, F. Acute Leukemia. Clinics in Laboratory Medicine 2002, 22 (1), 153-192. ##https://doi.org/10.1016/S0272-2712(03)00071-4##Lin, K.; Austin, G. Functional Activity of Three Distinct Myeloperoxidase (MPO) Promoters in Human Myeloid Cells. Leukemia 2002, 16 (6), 1143-1153. ##https://doi.org/10.1038/sj.leu.2402514##Verigou, E.; Chatzilygeroudi, T.; Lazaris, V.; De Lastic, A.-L.; Symeonidis, A. Immunophenotyping Myelodysplastic Neoplasms: The Role of Flow Cytometry in the Molecular Classification Era. Front. Oncol. 2024, 14, 1447001. ##https://doi.org/10.3389/fonc.2024.1447001##on behalf of the EuroFlow Consortium; Van Dongen, J. J. M.; Orfao, A. EuroFlow: Resetting Leukemia and Lymphoma Immunophenotyping. Basis for Companion Diagnostics and Personalized Medicine. Leukemia 2012, 26 (9), 1899-1907. ##https://doi.org/10.1038/leu.2012.121##Bain, B. J.; Béné, M. C. Morphological and Immunophenotypic Clues to the WHO Categories of Acute Myeloid Leukaemia. Acta Haematol 2019, 141 (4), 232-244. ##https://doi.org/10.1159/000496097##Koeffler, H.; Ranyard, J.; Pertcheck, M. Myeloperoxidase: Its Structure and Expression during Myeloid Differentiation. Blood 1985, 65 (2), 484-491. ##https://doi.org/10.1182/blood.V65.2.484.484##Charak, B. S.; Advani, S. H.; Karandikar, S. M.; Parikh, P. M.; Nair, C. N.; Das Gupta, A.; Gopal, R.; Tapan, K. S.; Nadkarni, K. S.; Kurkure, P. A.; Pai, S. K.; Pai, V. R. Sudan Black B Positivity in Acute Lymphoblastic Leukemia. Acta Haematol 1988, 80 (4), 199-202. ##https://doi.org/10.1159/000205637##Subramaniam, H. N.; Chaubal, K. A. Evaluation of Intracellular Lipids by Standardized Staining with a Sudan Black B Fraction. Journal of Biochemical and Biophysical Methods 1990, 21 (1), 9-16. ##https://doi.org/10.1016/0165-022X(90)90040-J##Cohn, P.; Emanuel, P.; Bozdech, M. Differences in Nonspecific Esterase from Normal and Leukemic Monocytes. Blood 1987, 69 (6), 1574-1579. ##https://doi.org/10.1182/blood.V69.6.1574.1574##Van Der Pan, K.; De Bruin-Versteeg, S.; Damasceno, D.; Hernández-Delgado, A.; Van Der Sluijs-Gelling, A. J.; Van Den Bossche, W. B. L.; De Laat, I. F.; Díez, P.; Naber, B. A. E.; Diks, A. M.; Berkowska, M. A.; De Mooij, B.; Groenland, R. J.; De Bie, F. J.; Khatri, I.; Kassem, S.; De Jager, A. L.; Louis, A.; Almeida, J.; Van Gaans-van Den Brink, J. A. M.; Barkoff, A.-M.; He, Q.; Ferwerda, G.; Versteegen, P.; Berbers, G. A. M.; Orfao, A.; Van Dongen, J. J. M.; Teodosio, C. Development of a Standardized and Validated Flow Cytometry Approach for Monitoring of Innate Myeloid Immune Cells in Human Blood. Front. Immunol. 2022, 13, 935879. ##https://doi.org/10.3389/fimmu.2022.935879##Guruprasad, K. P.; Vasudev, V.; Agrawal, H.; Thakur, M.; Krishan, A.; Sobti, R. C. Flow Cytometry: Historical Perspectives, Fundamentals, Past and Present Instrumentations, and Applications. In Flow Cytometry; Sobti, R. C., Krishan, A., Agrawal, D. K., Eds.; Springer Nature Singapore: Singapore, 2024; pp 1-25. ##https://doi.org/10.1007/978-981-97-4553-1_1##Rahman, K. Flow Cytometry Based Residual Disease Monitoring in Haematolymphoid Neoplasm. In Flow Cytometry; Sobti, R. C., Krishan, A., Agrawal, D. K., Eds.; Springer Nature Singapore: Singapore, 2024; pp 319-346. ##https://doi.org/10.1007/978-981-97-4553-1_19##Peters, J. M.; Ansari, M. Q. Multiparameter Flow Cytometry in the Diagnosis and Management of Acute Leukemia. Archives of Pathology & Laboratory Medicine 2011, 135 (1), 44-54. ##https://doi.org/10.5858/2010-0387-RAR.1##Denys, B.; Van Der Sluijs-Gelling, A. J.; Homburg, C.; Van Der Schoot, C. E.; De Haas, V.; Philippé, J.; Pieters, R.; Van Dongen, J. J. M.; Van Der Velden, V. H. J. Improved Flow Cytometric Detection of Minimal Residual Disease in Childhood Acute Lymphoblastic Leukemia. Leukemia 2013, 27 (3), 635-641. ##https://doi.org/10.1038/leu.2012.231##Diamond, L. W.; Nguyen, D. T.; Andreeff, M.; Maiese, R. L.; Braylan, R. C. A Knowlewldge‐based System for the Interpretation of Flow Cytometry Data in Leukemias and Lymphomas. Cytometry 1994, 17 (3), 266-273. ##https://doi.org/10.1002/cyto.990170310##Varma, N.; Naseem, S. Application of Flow Cytometry in Pediatric Hematology‐oncology. Pediatric Blood & Cancer 2011, 57 (1), 18-29. ##https://doi.org/10.1002/pbc.22954##Lacombe, F.; Belloc, F. Flow Cytometry Study of Cell Cycle, Apoptosis and Drug Resistance in Acute Leukemia. Hematol Cell Ther 1996, 38 (6), 495-504. ##https://doi.org/10.1007/s00282-996-0495-9##Brown, M.; Wittwer, C. Flow Cytometry: Principles and Clinical Applications in Hematology. Clinical Chemistry 2000, 46 (8), 1221-1229. ##https://doi.org/10.1093/clinchem/46.8.1221##Theunissen, P.; Mejstrikova, E.; Sedek, L.; Van Der Sluijs-Gelling, A. J.; Gaipa, G.; Bartels, M.; Sobral Da Costa, E.; Kotrová, M.; Novakova, M.; Sonneveld, E.; Buracchi, C.; Bonaccorso, P.; Oliveira, E.; Te Marvelde, J. G.; Szczepanski, T.; Lhermitte, L.; Hrusak, O.; Lecrevisse, Q.; Grigore, G. E.; Froňková, E.; Trka, J.; Brüggemann, M.; Orfao, A.; Van Dongen, J. J. M.; Van Der Velden, V. H. J. Standardized Flow Cytometry for Highly Sensitive MRD Measurements in B-Cell Acute Lymphoblastic Leukemia. Blood 2017, 129 (3), 347-357. ##https://doi.org/10.1182/blood-2016-07-726307##Karawajew, L.; Dworzak, M.; Ratei, R.; Rhein, P.; Gaipa, G.; Buldini, B.; Basso, G.; Hrusak, O.; Ludwig, W.-D.; Henze, G.; Seeger, K.; Von Stackelberg, A.; Mejstrikova, E.; Eckert, C. Minimal Residual Disease Analysis by Eight-Color Flow Cytometry in Relapsed Childhood Acute Lymphoblastic Leukemia. Haematologica 2015, 100 (7), 935-944. ##https://doi.org/10.3324/haematol.2014.116707##Modvig, S.; Hallböök, H.; Madsen, H. O.; Siitonen, S.; Rosthøj, S.; Tierens, A.; Juvonen, V.; Osnes, L. T. N.; Vålerhaugen, H.; Hultdin, M.; Matuzeviciene, R.; Stoskus, M.; Marincevic, M.; Lilleorg, A.; Ehinger, M.; Norén-Nystrøm, U.; Toft, N.; Taskinen, M.; Jónsson, O. G.; Pruunsild, K.; Vaitkeviciene, G.; Vettenranta, K.; Lund, B.; Abrahamsson, J.; Porwit, A.; Schmiegelow, K.; Marquart, H. V. Value of Flow Cytometry for MRD-Based Relapse Prediction in B-Cell Precursor ALL in a Multicenter Setting. Leukemia 2021, 35 (7), 1894-1906. ##https://doi.org/10.1038/s41375-020-01100-5##Vredenburgh, J. J.; Silva, O.; Tyer, C.; DeSOMBRE, K.; Abou-Ghalia, A.; Cook, M.; Layfield, L.; Peters, W. P.; Bast, R. C. A Comparison of Immunohistochemistry, Two-Color Immunofluorescence, and Flow Cytometry with Cell Sorting for the Detection of Micrometastatic Breast Cancer in the Bone Marrow. Journal of Hematotherapy 1996, 5 (1), 57-62. ##https://doi.org/10.1089/scd.1.1996.5.57##Wyatt, J. I.; Quirke, P.; Ward, D. C.; Clayden, A. D.; Dixon, M. F.; Johnston, D.; Bird, C. C. Comparison of Histopathological and Flow Cytometric Parameters in Prediction of Prognosis in Gastric Cancer. The Journal of Pathology 1989, 158 (3), 195-201. ##https://doi.org/10.1002/path.1711580305##Gerstner, A. O. H.; Mittag, A.; Laffers, W.; Dähnert, I.; Lenz, D.; Bootz, F.; Bocsi, J.; Tárnok, A. Comparison of Immunophenotyping by Slide-Based Cytometry and by Flow Cytometry. Journal of Immunological Methods 2006, 311 (1-2), 130-138. ##https://doi.org/10.1016/j.jim.2006.01.012##Tworek, J. A.; Singleton, T. P.; Schnitzer, B.; Hsi, E. D.; Ross, C. W. Flow Cytometric and Immunohistochemical Analysis of Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, and Plasmacytoid Small Lymphocytic Lymphoma. Am J Clin Pathol 1998, 110 (5), 582-589. ##https://doi.org/10.1093/ajcp/110.5.582##Ahuja, A.; Tyagi, S.; Seth, T.; Pati, H. P.; Gahlot, G.; Tripathi, P.; Somasundaram, V.; Saxena, R. Comparison of Immunohistochemistry, Cytochemistry, and Flow Cytometry in AML for Myeloperoxidase Detection. Indian J Hematol Blood Transfus 2018, 34 (2), 233-239. ##https://doi.org/10.1007/s12288-017-0849-1##Paredes‐Aguilera, R.; Romero‐Guzman, L.; Lopez‐Santiago, N.; Burbano‐Ceron, L.; Camacho‐Del Monte, O.; Nieto‐Martinez, S. Flow Cytometric Analysis of Cell‐surface and Intracellular Antigens in the Diagnosis of Acute Leukemia. American J Hematol 2001, 68 (2), 69-74. ##https://doi.org/10.1002/ajh.1155##Guillaume, N.; Penther, D.; Vaida, I.; Gruson, B.; Harrivel, V.; Claisse, J. . F.; Capiod, J. C.; Lefrere, J. J.; Damaj, G. CD66c Expression in B‐cell Acute Lymphoblastic Leukemia: Strength and Weakness. Int J Lab Hematology 2011, 33 (1), 92-96. ##https://doi.org/10.1111/j.1751-553X.2010.01254.x##Liu, M.; Weng, X.; Gong, S.; Chen, H.; Ding, J.; Guo, M.; Hu, X.; Wang, J.; Yang, J.; Tang, G. Flow Cytometric Analysis of CD64 Expression Pattern and Density in the Diagnosis of Acute Promyelocytic Leukemia: A Multi-Center Study in Shanghai, China. Oncotarget 2017, 8 (46), 80625-80637. ##https://doi.org/10.18632/oncotarget.20814##Lam, G.; Punnett, A.; Stephens, D.; Sung, L.; Abdelhaleem, M.; Hitzler, J. Value of Flow Cytometric Analysis of Peripheral Blood Samples in Children Diagnosed with Acute Lymphoblastic Leukemia. Pediatric Blood & Cancer 2018, 65 (1), e26738. ##https://doi.org/10.1002/pbc.26738##Raskovalova, T.; Berger, M. G.; Jacob, M.-C.; Park, S.; Campos, L.; Aanei, C. M.; Kasprzak, J.; Pereira, B.; Labarère, J.; Cesbron, J.-Y.; Veyrat-Masson, R. Flow Cytometric Analysis of Neutrophil Myeloperoxidase Expression in Peripheral Blood for Ruling out Myelodysplastic Syndromes: A Diagnostic Accuracy Study. Haematologica 2019, 104 (12), 2382-2390. ##https://doi.org/10.3324/haematol.2018.202275##Zhang, X.; Wang, L.-P.; Ziober, A.; Zhang, P. J.; Bagg, A. Ionized Calcium Binding Adaptor Molecule 1 (IBA1). American Journal of Clinical Pathology 2021, 156 (1), 86-99. ##https://doi.org/10.1093/ajcp/aqaa209##Rollins‐Raval, M. A.; Roth, C. G. The Value of Immunohistochemistry for CD14, CD123, CD33, Myeloperoxidase and CD68R in the Diagnosis of Acute and Chronic Myelomonocytic Leukaemias. Histopathology 2012, 60 (6), 933-942. ##https://doi.org/10.1111/j.1365-2559.2012.04175.x##Deghady, A. A. M.; Mansour, A. R.; Elfahham, assma A. A. A. E. The Value of Cytochemical Stains in the Diagnosis of Acute Leukemia. International Journal For Research In Health Sciences And Nursing 2016, 2 (5).##Resende, G. A. D.; Gileno, M. da C.; Moraes-Souza, H.; Carlos, A. M.; Leal, A. S.; Martins, P. R. J. The Role of Cytochemistry in the Diagnosis of Acute Leukemias. International Journal of Health Sciences and Research 2017, 7 (8).##Hamid, Dr. G. A.; Harize, Dr. I. B. BONE MARROW MORPHOLOGY AND CYTOCHEMICAL STAINING IN DIAGNOSIS AND CLASSIFICATION OF ACUTE LEUKEMIA. European Journal of Biomedical AND Pharmaceutical sciences 2018, 5 (8), 574-583.##Venkatesan, S.; Boj, S.; Nagaraj, S. A STUDY OF CLINICO-HEMATOLOGICAL PROFILE IN ACUTE LEUKEMIA WITH CYTOCHEMICAL CORRELATION. International Journal of Academic Medicine and Pharmacy 2023, 5 (4), 893-898.## ##

Chemokine-guided Stem Cell Migration for Retinal Regeneration: A Systematic Review 2 2 Background: Retinal degeneration remains one of the predominant causes of blindness, with extremely low regenerative capacity in the mammalian retina. Stem cell-based therapy is a highly promising approach for retinal regeneration, but efficient stem cell migration and integration are significant challenges. This systematic review aimed to discuss chemokine-directed stem cell migration in retinal regeneration, summarising important chemokines, signalling pathways, and therapeutic opportunities. Methods: A systematic literature search was done in PubMed, Embase, Scopus, Web of Science, Cochrane Library, CINAHL, and PsycINFO between January 2010 and January 2025. Preclinical and clinical studies that explored chemokine-stimulated stem cell migration during retinal repair were included based on the inclusion criteria. The data extracted included chemokine-receptor interaction, signalling pathways, type of stem cells, route of delivery, and outcomes of retinal repair. The ROBINS-I tool was used to evaluate the risk of bias. Results: In 384 studies, 12 were included. The SDF-1/CXCL12-CXCR4 pathway was explored in the most detail, augmenting stem cell homing and integration. Other pathways, such as ERK/MAPK, PI3K/Akt, and JAK-STAT, also played a role in migration and survival. Chemokine-modulated therapies enhanced retinal function and repair, but immune responses and delivery issues remain. New approaches such as biodegradable scaffolds, magnetic targeting, and chemically engineered chemokines were discovered to optimise stem cell localisation and efficacy. Conclusion: Chemokine-directed stem cell migration is an exciting field for retinal regeneration, which has the potential to improve targeted cell delivery and integration. While SDF-1/CXCL12 remains the gold standard, other pathways and new delivery pathways are also extremely capable. Augmenting chemokine-based therapies, overcoming immunological barriers, and translating them into the clinic in the future will be paramount to optimising stem cell-mediated retinal repair. 26 34 2025/07/42025/07/142025/08/192025/07/24 1404/5/2 2025/09/242025/09/112025/09/112025/09/11 1404/6/20 Ashish Chander Ashish Chander Teerthanker Mahaveer University, Teerthanker Mahaveer Medical College & Research Centre (TMMC & RC), Moradabad, Uttar Pradesh, India. Vinod Kumar Singh Vinod Kumar Singh Teerthanker Mahaveer University, Teerthanker Mahaveer Medical College & Research Centre (TMMC & RC), Moradabad, Uttar Pradesh, India. Sonika Sharma Sonika Sharma Teerthanker Mahaveer University, Teerthanker Mahaveer Medical College & Research Centre (TMMC & RC), Moradabad, Uttar Pradesh, India. Prithpal Singh Matreja Prithpal Singh Matreja Teerthanker Mahaveer University, Teerthanker Mahaveer Medical College & Research Centre (TMMC & RC), Moradabad, Uttar Pradesh, India. singhmatrejaprithpal@gmail.com Chemokines SDF-1/CXCL12 PI3K/Akt pathway JAK-STAT pathway X. Wei, Z. Zhang, H. Zeng, X. Wang, W. Zhan, N. Qiaoet al., "Regeneration of functional retinal ganglion cells by neuronal identity reprogramming", 2020.##P. Williams, L. Benowitz, J. Goldberg, & Z. He, "Axon regeneration in the mammalian optic nerve", Annual Review of Vision Science, vol. 6, no. 1, p. 195-213, 2020.##S. Behtaj, A. Öchsner, Y. Anissimov, & M. Rybachuk, "Retinal tissue bioengineering, materials and methods for the treatment of glaucoma", Tissue Engineering and Regenerative Medicine, vol. 17, no. 3, p. 253-269, 2020.##C. Petrash, A. Palestine, & M. Soler, "Immunologic rejection of transplanted retinal pigmented epithelium: mechanisms and strategies for prevention", Frontiers in Immunology, vol. 12, 2021.##A. Khan, T. Utheim, & J. Eidet, "Retinal pigment epithelium transplantation: past, present, and future", Journal of Ophthalmic and Vision Research, vol. 17, no. 4, 2022.##L. Finocchio, M. Zeppieri, A. Gabai, L. Spadea, & C. Salati, "Recent advances of adipose-tissue-derived mesenchymal stem cell-based therapy for retinal diseases", Journal of Clinical Medicine, vol. 12, no. 22, p. 7015, 2023.##P. Sharma, S. Gupta, M. Chaudhary, S. Mitra, B. Chawla, M. Khursheedet al., "Biphasic role of tgf-β signaling during müller glia reprogramming and retinal regeneration in zebrafish", Iscience, vol. 23, no. 2, p. 100817, 2020.##M. Lahne, M. Nagashima, D. Hyde, & P. Hitchcock, "Reprogramming müller glia to regenerate retinal neurons", Annual Review of Vision Science, vol. 6, no. 1, p. 171-193, 2020.##M. Lee, J. Wan, & D. Goldman, "Tgfb3 collaborates with pp2a and notch signalling pathways to inhibit retina regeneration", Elife, vol. 9, 2020. ##https://doi.org/10.7554/eLife.55137##T. Hoang, J. Wang, P. Boyd, F. Wang, C. Santiago, L. Jianget al., "Gene regulatory networks controlling vertebrate retinal regeneration", Science, vol. 370, no. 6519, 2020.##C. Yu, D. Li, Y. Lv, X. Shi, R. Zhang, W. [#], "Nanotherapy for neural retinal regeneration", Advanced Science, 2025.##L. Li, X. Liu, B. Gaihre, S. Park, Y. Li, A. Terzicet al., "Sdf-1α/op/bp composites enhance the migrating and osteogenic abilities of mesenchymal stem cells", Stem Cells International, vol. 2021, p. 1-12, 2021.##J. Lee, R. Zhang, M. Yan, S. Duggineni, D. Wakeman, W. Nileset al., "Chemical mutagenesis of a gpcr ligand: detoxifying "inflame-attraction" to direct therapeutic stem cell migration", Proceedings of the National Academy of Sciences, vol. 117, no. 49, p. 31177-31188, 2020.##L. Wang, H. Li, J. Lin, R. He, M. Chen, Y. [#], "Ccr2 improves homing and engraftment of adipose-derived stem cells in dystrophic mice", Stem Cell Research & Therapy, vol. 12, no. 1, 2021.##C. Hu, H. La, X. Wei, Y. Zhou, Q. Ou, Z. Chenet al., "Transplantation site affects the outcomes of adipose-derived stem cell-based therapy for retinal degeneration", Stem Cells International, vol. 2020, p. 1-12, 2020.##J. Soucy, L. Todd, E. Kriukov, M. Phay, T. Reh, & P. Baranov, "Introduced chemokine gradients guide transplanted and regenerated retinal neurons toward their natural position in the retina", 2022.##A. Ozga, M. Chow, & A. Luster, "Chemokines and the immune response to cancer", Immunity, vol. 54, no. 5, p. 859-874, 2021.##G. Xiu, X. Li, Y. Yin, J. Li, B. Li, X. Chenet al., "Sdf-1/cxcr4 augments the therapeutic effect of bone marrow mesenchymal stem cells in the treatment of lipopolysaccharide-induced liver injury by promoting their migration through pi3k/Akt signalling pathway", Cell Transplantation, vol. 29, p. 096368972092999, 2020.##K. Shimizu, Y. Maeda, M. Kuwabara, M. Hosogai, T. Mitsuhara, M. Takedaet al., "Impact of cranial bone-derived mesenchymal stem cell transplantation for functional recovery in experimental spinal cord injury", 2022.##K. Kohli, V. Pillarisetty, & T. Kim, "Key chemokines direct migration of immune cells in solid tumors", Cancer Gene Therapy, vol. 29, no. 1, p. 10-21, 2021.##Y. Chen, Z. Shao, E. Jiang, X. Zhou, L. Wang, H. Wanget al., "Ccl21/ccr7 interaction promotes emt and enhances the stemness of oscc via a jak2/stat3 signaling pathway", Journal of Cellular Physiology, vol. 235, no. 9, p. 5995-6009, 2020.##H. Hahn, C. Daly, J. Little, N. Perry, E. Flores-Espinoza, A. Inoueet al., "Endosomal chemokine receptor signalosomes regulate central mechanisms underlying cell migration",, 2022.##Daher ID, Moura MI, Murad AC, Ferrari RS, Neiva EB, Liedtke FS, Zotarelli Filho IJ. Major clinical findings of cellular therapy for intravitreal use in ischemic retinopathy and macular degeneration: a systematic review. MedNEXT Journal of Medical and Health Sciences. 2022 Aug 28;3[3].##Soucy JR, Todd L, Kriukov E, Phay M, Reh TA, Baranov P. Introduced chemokine gradients guide transplanted and regenerated retinal neurons toward their natural position in the retina. bioRxiv. 2022 Oct 1:2022-09.##Unachukwu UJ, Warren A, Li Z, Mishra S, Zhou J, Sauane M, Lim H, Vazquez M, Redenti S. Predicted molecular signaling guiding photoreceptor cell migration following transplantation into damaged retina. Scientific reports. 2016 Mar 3;6[1]:22392.##Enzmann V, Lecaudé S, Kruschinski A, Vater A. CXCL12/SDF-1-dependent retinal migration of endogenous bone marrow-derived stem cells improves visual function after pharmacologically induced retinal degeneration. Stem cell reviews and reports. 2017 Apr; 13:278-86.##Wang J, Zhang W, He GH, Wu B, Chen S. Transfection with CXCR4 potentiates homing of mesenchymal stem cells in vitro and therapy of diabetic retinopathy in vivo. International Journal of Ophthalmology. 2018;11[5]:766.##Sharma R, Khristov V, Rising A, Jha BS, Dejene R, Hotaling N, Li Y, Stoddard J, Stankewicz C, Wan Q, Zhang C. Clinical-grade stem cell-derived retinal pigment epithelium patch rescues retinal degeneration in rodents and pigs. Science translational medicine. 2019 Jan 16;11[475]: eaat5580.##Yanai A, Häfeli UO, Metcalfe AL, Soema P, Addo L, Gregory-Evans CY, Po K, Shan X, Moritz OL, Gregory-Evans K. Focused magnetic stem cell targeting to the retina using superparamagnetic iron oxide nanoparticles. Cell transplantation. 2012 Jun;21[6]:1137-48.##Xu, F., Shi, J., Yu, B., Ni, W., Wu, X., & Gu, Z. . Chemokines mediate mesenchymal stem cell migration toward gliomas in vitro. Oncology Reports, 23[6], 1561-1567.##Subramani M, Van Hook MJ, Qiu F, Ahmad I. Human Retinal Ganglion Cells Respond to Evolutionarily Conserved Chemotropic Cues for Intra Retinal Guidance and Regeneration. Stem Cells. 2023 Nov 1;41[11]:1022-36.##Pena J, Dulger N, Singh T, Zhou J, Majeska R, Redenti S, Vazquez M. Controlled microenvironments to evaluate chemotactic properties of cultured Müller glia. Experimental eye research. 2018 Aug 1; 173:129-37.##Fukushima Y, Okada M, Kataoka H, Hirashima M, Yoshida Y, Mann F, Gomi F, Nishida K, Nishikawa SI, Uemura A. Sema3E-PlexinD1 signaling selectively suppresses disoriented angiogenesis in ischemic retinopathy in mice. The Journal of clinical investigation. 2011 May 2;121[5]:1974-85.##Lee JP, Zhang R, Yan M, Duggineni S, Wakeman DR, Niles WL, Feng Y, Chen J, Hamblin MH, Han EB, Gonzalez R. Chemical mutagenesis of a GPCR ligand: Detoxifying "inflammo-attraction" to direct therapeutic stem cell migration. Proceedings of the National Academy of Sciences. 2020 Dec 8;117[49]:31177-88.## ##

Effects of Metformin on Leukemia: Biological Mechanisms, Targets, and Treatment Possibilities 2 2 Metformin is a widely prescribed medication for managing diabetes, but it also affects cancer cell metabolism through both direct and indirect mechanisms. Cancer cells often divide rapidly, and this quick division, along with metabolic changes, increases intracellular free radicals and inhibits the enzyme hexokinase. This inhibition prevents the conversion of glucose to glucose-6-phosphate, leading to glucose deprivation and subsequently causing mitochondrial depolarization and apoptosis in cancer cells. KDM1A is an epigenetic regulator that plays a vital role in cancer development. Both KDM1A and metformin influence autophagy and cancer-related pathways, and their interaction could lead to new treatment strategies. Metformin reduces oxidative stress and activates ATM signaling, since the ATM gene encodes a tumor suppressor protein that helps repair DNA mutations during stress. Additionally, the drug enhances the recognition of damaged DNA by increasing ATM protein levels. In acute myeloid leukemia (AML), leukemic stem cells (LSCs) often develop resistance after chemotherapy, which greatly contributes to treatment failures. This article aims to explore how metformin affects LSCs, DNA repair gene expression, and related biological mechanisms, as well as its targets and therapeutic potential. This study reviews existing articles about metformin's mechanisms in leukemia. Metformin shows significant potential for reducing mortality rates associated with various cancers, including leukemia. 35 45 2025/07/42025/07/142025/08/192025/07/242025/07/17 1404/4/26 2025/09/242025/09/112025/09/112025/09/112025/09/17 1404/6/26 Parisa Dana Parisa Dana Islamic Azad University،Science and Research Branch, Tehran, Iran. parisadana95@gmail.com Abdolkhalegh Deezagi Abdolkhalegh Deezagi National Institute of Genetic Engineering and Biotechnology, Tehran, Iran. Metformin Leukemia Metabolic changes Mechanisms KDM1A gene ATM Leukemia stem cells Vivek Asati DKM, Sanjay Kumar Bharti. . PI3K/Akt/mTOR and Ras/Raf/MEK/ERK signaling pathways inhibitors as anticancer agents: Structural and pharmacological perspectives. Eur J Med Chem. 2016 Feb 15.##Monika Katharina Guenther UG, Simone Fulda. Synthetic lethal interaction between PI3K/Akt/mTOR and Ras/MEK/ERK pathway inhibition in rhabdomyosarcoma. Cancer Lett. 2013 Sep 1.##Zehtabcheh S, Yousefi AM, Salari S, Safa M, Momeny M, Ghaffari SH, et al. Abrogation of histone deacetylases (HDACs) decreases survival of chronic myeloid leukemia cells: New insight into attenuating effects of the PI3K/c‐Myc axis on panobinostat cytotoxicity. Cell Biology International. 2021;45(5):1111-21.##Rosalyn D Ferguson EJG, Eyal J Scheinman, Rawan Damouni, Derek LeRoith. The epidemiology and molecular mechanisms linking obesity, diabetes, and cancer Vitam Horm. 2013.##Emily Jane Gallagher DL. Obesity and Diabetes: The Increased Risk of Cancer and Cancer-Related Mortality Physiol Rev. 2015 Jul.##Claire Oudin JB, Yves Bertrand, Camille Vercasson, Frédérique Thomas,et al. Prevalence and characteristics of metabolic syndrome in adults from the French childhood leukemia survivors' cohort: a comparison with controls from the French population. Haematologica. 2018 Jan 19.##Paul Saultier PA, Yves Bertrand, Camille Vercasson, Claire Oudin, et al. . Metabolic syndrome in long-term survivors of childhood acute leukemia treated without hematopoietic stem cell transplantation: an L.E.A. study Haematologica. 2016 Dec.##Varsha P Brahmkhatri CP, Hanudatta S Atreya. Insulin-like growth factor system in cancer: novel targeted therapies. Biomed Res Int. 2015.##Danielle Novetsky Friedman PH, Chaya S Moskowitz , Maya Suzuki, et al. . Cardiovascular Risk Factors in Survivors of Childhood Hematopoietic Cell Transplantation Treated with Total Body Irradiation: A Longitudinal Analysis Biol Blood Marrow Transplant. 2017 Mar.##Kerri A Nottage KKN, Chenghong Li, Deokumar Srivastava, Leslie L Robison, et al. Metabolic syndrome and cardiovascular risk among long-term survivors of acute lymphoblastic leukaemia - From the St. Jude Lifetime Cohort Br J Haematol. 2014 May.##Maria Felicia Faienza MD, Paola Giordano, Luciano Cavallo, Maria Grano, et al. Metabolic syndrome in childhood leukemia survivors: a meta-analysis Endocrine, 2015 Jun.##Maja S Misirkic Marjanovic LMV, Ana R Despotovic, Marina M Stamenkovic, Kristina D Janjetovic. . Dual anticancer role of metformin: an old drug regulating AMPK dependent/independent pathways in metabolic, oncogenic/tumorsuppresing and immunity context. Am J Cancer Res. 2021 Nov 15.##Shoeb Ikhlas MA. Metformin: Insights into its anticancer potential with special reference to AMPK dependent and independent pathways Life Sci. 2017 Sep 15.##Yeon Kyung Choi K-GP. Metabolic Roles of AMPK and Metformin in Cancer Cells. Mol Cells. 2013 Jun 19.##Sang-Min Jeon NC, N. Hay. AMPK regulates NADPH homeostasis to promote tumour cell survival during energy stress. Nature. 09 May 2012.##David B Shackelford EA, Laurie Gerken, Debbie S Vasquez, Atsuko Seki, et al. LKB1 inactivation dictates therapeutic response of non-small cell lung cancer to the metabolism drug phenformin Cancer Cell. 2013 Feb 11.##Chengmin Deng LX, Yang Chen, Kaifeng Wu, Jie Wu. Metformin induces ferroptosis through the Nrf2/HO-1 signaling in lung cancer BMC Pulm Med. 2023 Sep 25.##Lingya Fang SL, Liuyuan Fang, Junxin Yu, Nisile Kakongma, et al. . Metformin ameliorates gestational diabetes mellitus via inhibiting ferroptosis of trophoblasts through the Nrf2/HO-1 signaling pathway Free Radic Res. 2025 Feb.##Shuyan Li SL, Lei Wang, Shasha Liu, Lei Zhang, et al. . Effects of amygdalin on ferroptosis and oxidative stress in diabetic retinopathy progression via the NRF2/ARE signaling pathway. Exp Eye Res. 2023 Sep.##Ewis SA A-RM. Effect of metformin on glutathione and magnesium in normal and streptozotocin-induced diabetic rats. J Appl Toxicol. 1995 Sep-Oct.##S A Ewis MSA-R. Influence of atenolol and/or metformin on glutathione and magnesium levels in diabetic rats. J Appl Toxicol. 1997 Nov-Dec.##https://doi.org/10.1002/(SICI)1099-1263(199711/12)17:63.0.CO;2-B##Zenat K Salman RR, Eman Selima, Ashgan El Sarha, Menna A Ismail. The combined effect of metformin and L-cysteine on inflammation, oxidative stress and insulin resistance in streptozotocin-induced type 2 diabetes in rats Eur J Pharmacol. 2013 Aug 15.##Chen F XH, Wang J, Ding X, Shu G, Mei Z. Antidiabetic effect of total flavonoids from Sanguis draxonis in type 2 diabetic rats. . J Ethnopharmacol. 2013 Oct 7.##Yanwen Wang TC, Benjamin Perry, Cécile Beaurepaire, Ling Qin. Hypoglycemic and insulin-sensitizing effects of berberine in high-fat diet- and streptozotocin-induced diabetic rats Metabolism. 2011 Feb.##Reed MJ MK, Entes LJ, Claypool MD, Pinkett JG, et al. Effect of masoprocol on carbohydrate and lipid metabolism in a rat model of Type II diabetes. Diabetologia. 1999 Jan.##Nasri H BA, Ardalan MR, Mardani S, Momeni A, et al. Bright renoprotective properties of metformin: beyond blood glucose regulatory effects. . Iran J Kidney Dis. 2013 Nov.##Luke Kennedy JKS, Mary-Ellen Harper, Miroslava Cuperlovic-Culf. . Role of Glutathione in Cancer: From Mechanisms to Therapies. Biomolecules. 2020 Oct 9.##Bansal A SM. Glutathione metabolism in cancer progression and treatment resistance. J Cell Biol. 2018 Jul 2.##Singh S KA, Gupta AK. Role of glutathione in cancer pathophysiology and therapeutic interventions. . J Exp Ther Oncol. 2012.##Thomas Farge ES, Fabienne de Toni, Nesrine Aroua, Mohsen Hosseini, et al. Chemotherapy-Resistant Human Acute Myeloid Leukemia Cells Are Not Enriched for Leukemic Stem Cells but Require Oxidative Metabolism. Cancer Discov. 2017 Jul.##Anna Polak EB, Beata Krzymieniewska, Jolanta Wozniak, Marta Stojak, et al. SYK inhibition targets acute myeloid leukemia stem cells by blocking their oxidative metabolism. Cell Death & Disease 06 November 2020.##Mohsen Hosseini HRR, Nesrine Aroua, Claudie Bosc, Thomas Farge, et al. Targeting Myeloperoxidase Disrupts Mitochondrial Redox Balance and Overcomes Cytarabine Resistance in Human Acute Myeloid Leukemia Cancer Res. 2019 Oct 15.##Ma J LB, Yu D, Zuo Y, Cai R, Yang J, Cheng J. SIRT3 deacetylase activity confers chemoresistance in AML via regulation of mitochondrial oxidative phosphorylation. . Br J Haematol. 2019 Oct.##Kim YR EJ, Kim SJ, Jeung HK, Cheong JW,et al. Myeloperoxidase expression as a potential determinant of parthenolide-induced apoptosis in leukemia bulk and leukemia stem cells. . J Pharmacol Exp Ther. 2010 Nov.##Tony Marchand SP. Leukemic Stem Cells: From Leukemic Niche Biology to Treatment Opportunities Front Immunol. 2021 Oct 15.##Omid Karimdadi Sariani SE, Elahe Kazemi, Kimia Rafiei Buzhani, Farhad Zaker. Pathogenic and therapeutic roles of cytokines in acute myeloid leukemia Cytokine. 2021 Jun.##Thummalapalli R KH, Gojo I, Zeidner JF. Immune Checkpoint Inhibitors in AML-A New Frontier. . Curr Cancer Drug Targets. 2020.##Tayaba Ismail H-KL, Chowon Kim, Taejoon Kwon, Tae Joo Park,et al. . KDM1A microenvironment, its oncogenic potential, and therapeutic significance. Epigenetics Chromatin. 2018 Jun 19.##Amir Hosseini SM. A comprehensive review of lysine-specific demethylase 1 and its roles in cancer. Epigenomics. 2017 Aug.##Carmen Brenner JL, Martin Bizet, Matladi Ndlovu, Eleonore Josseaux, et al. The interplay between the lysine demethylase KDM1A and DNA methyltransferases in cancer cells is cell cycle dependent Oncotarget. 2016 Sep 13.##Huifang Zhang QG, Shuo Tan, Jia You, Cong Lyu, et al. SET8 prevents excessive DNA methylation by methylation-mediated degradation of UHRF1 and DNMT1 Nucleic Acids Res. 2019 Sep 26.##Suli Lv XZ, Erlei Zhang, Yingying Yan, Xianyun Ma , et al. Lysine demethylase KDM1A promotes cell growth via FKBP8-BCL2 axis in hepatocellular carcinoma. J Biol Chem. 2022 Aug 13.##E Cuyàs SF-A, S Verdura, R Á-F García, J Stursa, et al. Metformin regulates global DNA methylation via mitochondrial one-carbon metabolism. Oncogene. 23 October 2017.##Elisabet Cuyàs SV, Begoña Martin-Castillo, Javier A Menendez. . Metformin: Targeting the Metabolo-Epigenetic Link in Cancer Biology Front Oncol. 2021 Feb 2.##Maria V Liberti JWL. The Warburg Effect: How Does it Benefit Cancer Cells? Trends Biochem Sci. 2016 Jan 5.##Ping-Chih Ho JDB, Andrew N Macintyre, Matthew Staron, Xiaojing Liu,et al. . Phosphoenolpyruvate Is a Metabolic Checkpoint of Anti-tumor T Cell Responses Cell. 2015 Sep 10.##Hou AJ CL, Chen YY. Navigating CAR-T cells through the solid-tumour microenvironment. . Nat Rev Drug Discov. 2021 Jul.##Sukumar M RR, Restifo NP. Nutrient Competition: A New Axis of Tumor Immunosuppression. Cell. 2015 Sep 10.##Md Nasim Uddin DWT. T Lymphocyte Integrated Endoplasmic Reticulum Ca2+ Store Signaling Functions Are Linked to Sarco/Endoplasmic Reticulum Ca2+-ATPase Isoform-Specific Levels of Regulation Int J Mol Sci. 2025 Apr 27.##Gui-Min Wen X-YX, Pu Xia. Metabolism in Cancer Stem Cells: Targets for Clinical Treatment Cells. 2022 Nov 26.##Huang J LJ. Multiple Dynamics in Tumor Microenvironment Under Radiotherapy. Adv Exp Med Biol. 2020.##Yifei Zhu XL, Lei Wang, Xiwei Hong, Jie Yang. Metabolic reprogramming and crosstalk of cancer-related fibroblasts and immune cells in the tumor microenvironment Front Endocrinol (Lausanne). 2022 Aug 15.##Eliza Vakana JKA, Heather Glaser, Nicholas J Donato, Leonidas C Platanias. . Antileukemic effects of AMPK activators on BCR-ABL-expressing cells. Blood. 2011 Oct 21.##Mario Notari PN, Ramasamy Santhanam, Bradley W Blaser, Ji-Suk Chang. . A MAPK/HNRPK pathway controls BCR/ABL oncogenic potential by regulating MYC mRNA translation Blood. 2006 Mar 15.##Pranav Gupta RJK, Liuya Wei, Fang Wang, XiaoKun Wang, et al. PBA2, a novel inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia Cancer Lett. 2016 Dec 28.##Kim SJ JK, Yan HH, Son MK, Fang Z, et al. HS-543 induces apoptosis of Imatinib-resistant chronic myelogenous leukemia with T315I mutation. Oncotarget. 2015 Jan 30.##Ali. MAM. Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: An Evolving Paradigm of Molecularly Targeted Therapy Mol Diagn Ther. 2016 Aug.##Yang K FL. Mechanisms of resistance to BCR-ABL TKIs and the therapeutic strategies: A review. Crit Rev Oncol Hematol. 2015 Mar.##Andjela Petrovic IJ, Bojan Stojanovic, Milica Dimitrijevic Stojanovic, Bojana S Stojanovic, et al. Harnessing Metformin's Immunomodulatory Effects on Immune Cells to Combat Breast Cancer. Int J Mol Sci. 2024 May 28.##Faye K Tsogas DM, Peter C Hart. Possible Role of Metformin as an Immune Modulator in the Tumor Microenvironment of Ovarian Cancer. Int J Mol Sci. 2021 Jan 16.##Yi Zhang FZ, Jiaheng Guan, Lukun Zhou, Baoan Chen. Action Mechanism of Metformin and Its Application in Hematological Malignancy Treatments: A Review. Biomolecules 2023 Jan 29.##Qian Wang 1 XW. Research Progress on the Use of Metformin in Leukemia Treatment. Curr Treat Options Oncol. 2024 Jan 30.##Min Hu YC, Tao Ma, Li Jing. Repurposing Metformin in hematologic tumor: State of art. Curr Probl Cancer. 2023 Aug.##Papachristou S PD, Papanas N. Reduced Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma in Type 2 Diabetes Mellitus: Will Metformin Never Stop Its Pleasant Surprises? . Adv Ther. 2022 Jun.##Chang SH LS, O'Brian KK, Thomas TS, Colditz GA, et al. Association between metformin use and progression of monoclonal gammopathy of undetermined significance to multiple myeloma in US veterans with diabetes mellitus: a population-based retrospective cohort study. Lancet Haematol. 2015 Jan.##Wang Y XW, Yan Z, Zhao W, Mi J, et al. Metformin induces autophagy and G0/G1 phase cell cycle arrest in myeloma by targeting the AMPK/mTORC1 and mTORC2 pathways. J Exp Clin Cancer Res. 2018 Mar 20.##Emilia Amengual-Cladera PMM-B, Andrea Morán-Costoya, Jorge Sastre-Serra, Daniel Gabriel Pons, et al. . Metformin: From Diabetes to Cancer-Unveiling Molecular Mechanisms and Therapeutic Strategies. Biology (Basel). 2024 Apr 27.##Zaid Sirhan AAN, Nadeen Anabtawi, Anita Thyagarajan, Ravi P Sahu. Metformin-Based Combination Approaches for Triple-Negative Breast Cancer Pharmaceutics. 2025 Apr 24.##Zhangyuan Gu FY, Hong Luo, Xiaoguang Li, Yue Gong, et al. . Metformin sensitizes triple-negative breast cancer to histone deacetylase inhibitors by targeting FGFR4. J Biomed Sci. 2025 Mar 17.##Hélène Marijon DHL, LingWen Ding, Haibo Sun, Sigal Gery, et al. Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells Biomed Pharmacother, 2018 Mar.##Ido Laskov PA-N, Oreekha Amin, Charles-Andre Philip, Marie-Claude Beauchamp,et al. Metformin Increases E-cadherin in Tumors of Diabetic Patients With Endometrial Cancer and Suppresses Epithelial-Mesenchymal Transition in Endometrial Cancer Cell Lines. Int J Gynecol Cancer. 2016 Sep.##Marzena Łazarczyk DS, Michel-Edwar Mickael, Kinga Jaskuła, Agata Nawrocka, et al. . Opioid System and Epithelial-Mesenchymal Transition Pharmaceuticals (Basel). 2025 Jan 17.##Marconi GD FL, Rajan TS, Pierdomenico SD, Trubiani O, et al. Epithelial-Mesenchymal Transition (EMT): The Type-2 EMT in Wound Healing, Tissue Regeneration and Organ Fibrosis. Cells. 2021 Jun 23.##Yan T JX, Guo X, Chen W, Tang D,et al. Electric field-induced suppression of PTEN drives epithelial-to-mesenchymal transition via mTORC1 activation. J Dermatol Sci. 2017 Feb.##Giulia Biondani J-FP. Metformin, an Anti-diabetic Drug to Target Leukemia. Front Endocrinol (Lausanne). 2018 Aug 10.##Jeongho Kim Y-JY. Regulation of organelle function by metformin. IUBMB Life. 2017 Jul.##Hongying An LH. Current understanding of metformin effect on the control of hyperglycemia in diabetes J Endocrinol. 2016 Mar.##Marc Foretz BG, Benoit Viollet. . Understanding the glucoregulatory mechanisms of metformin in type 2 diabetes mellitus Nat Rev Endocrinol. 2019 Oct.##Lin Zhu KY, Zhe Ren, Detao Yin, Yubing Zhou, et al. . Metformin as anticancer agent and adjuvant in cancer combination therapy: Current progress and future prospect. Transl Oncol. 2024 Mar 30.##Deng J PM, Wang Z, Zhou S, Xiao D, et al. Novel application of metformin combined with targeted drugs on anticancer treatment. Cancer Sci. 2019 Jan.##Fereshtehsadat Jalali FF, Afrah Sepehr, Jaber Zafari, Behnam Omidi Sarajar, et al. Synergistic anticancer effects of doxorubicin and metformin combination therapy: A systematic review Transl Oncol. 2024 Jul.##Zainab Sabry Othman Ahmed MG, Yassen Abdullah, Reda Saber Ibrahim Ahmed, Q Ping Dou. . Repurposing of Metformin for Cancer Therapy: Updated Patent and Literature Review Recent Pat Anticancer Drug Discov, 2021.##AP. A. Rethinking sex determination of non-gonadal tissues. Curr Top Dev Biol. 2019.##Cabrera Zapata LE G-SL, Cambiasso MJ, Arevalo MA. Genetics and Epigenetics of the X and Y Chromosomes in the Sexual Differentiation of the Brain. Int J Mol Sci. 2022 Oct 14.##Jung Won Park JHL, Ye Hyun Park, Soo Jung Park, Jae Hee Cheon, et al. Sex-dependent difference in the effect of metformin on colorectal cancer-specific mortality of diabetic colorectal cancer patients World J Gastroenterol. 2017 Jul 28.##Andrew Dunford DMW, Virginia Savova, Steven E Schumacher, John P Cleary, et al. Tumor-suppressor genes that escape from X-inactivation contribute to cancer sex bias Nat Genet. 2017 Jan.##S. S-R. Cancer genetics: X-inactivation and cancer incidence. Nat Rev Cancer. 2016 Dec 21.##Shahar Shohat EV, Sagiv Shifman. Gene essentiality in cancer cell lines is modified by the sex chromosomes. Genome Res. 2022 Nov-Dec.##Wolstenholme JT RE, Bekiranov S. Sexual differentiation in the developing mouse brain: contributions of sex chromosome genes. Genes Brain Behav. 2013 Mar.##Meher Bolisetti Gayatri RKK, Dorababu Patchva, Nagaraj Velugonda, Sadashivudu Gundeti. Metformin exerts antileukemic effects by modulating lactate metabolism and overcomes imatinib resistance in chronic myelogenous leukemia FEBS J. 2023 Sep.##Eduardo Alvarado-Ortiz MAS-S. Hypoxic link between cancer cells and the immune system: The role of adenosine and lactate Oncol Res. 2025 Jul 18.##Isabella Spinello CL, Ernestina Saulle. Metabolic Function and Therapeutic Potential of CD147 for Hematological Malignancies: An Overview Int J Mol Sci. 2024 Aug 23.##Li X YX, Dai D, Song X, Xu W. The altered glucose metabolism in tumor and a tumor acidic microenvironment associated with extracellular matrix metalloproteinase inducer and monocarboxylate transporters. Oncotarget. 2016 Apr 26.##Chengxiang Liu LY, Tingting Gao, Xingxing Yuan, Ousman Bajinka, et al. A mini-review-cancer energy reprogramming on drug resistance and immune response. Transl Oncol. 2024 Aug 19.##Wenxuan Zou ZH, Zihan Wang, Qian Liu. . Targeting glutamine metabolism as a potential target for cancer treatment. J Exp Clin Cancer Res. 2025 Jul 1.##R Ilaya Kumar KJ, Karan Raj Rai, Harshnna Gururajan, Koustav Sarkar. Targeting epigenetic modifications as an emerging immunotherapeutic strategy for cancers Immunol Res. 2025 Aug 19.##R. K. Research Progress in Hematological Malignancies: A Molecular Genetics Perspective. Genes (Basel). 2025 May 29.##Yoshida. GJ. Metabolic Reprogramming: The Emerging Concept and Associated Therapeutic Strategies. J Exp Clin Cancer Res. 2015 Oct 6.##Martine Cordier-Bussat CT, Pierre Sujobert, Laurent Genestier, Éric Fontaine. . [Even the Warburg effect can be oxidized: metabolic cooperation and tumor development] Med Sci (Paris). 2018 Aug-Sep.##Silvia Jimenez-Morales KB, Nirmalya Saha, Amrita Basu, Kathy L McGraw. Editorial: Understanding leukemia biology using genome editing techniques. Front Oncol. 2023 Nov 7.##Daniel A Arber AO, Robert Hasserjian, Jürgen Thiele, Michael J Borowitz, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. blood. 2016 May 19.##Haipeng Shao WW, Jinming Song, Guilin Tang, Xiaohui Zhang, et al. Myeloid/lymphoid neoplasms with eosinophilia and FLT3 rearrangement Leuk Res. 2020 Dec.##James W Vardiman NLH, Richard D Brunning. The World Health Organization (WHO) classification of the myeloid neoplasms Blood. 2002 Oct 1.##Vardiman JW TJ, Arber DA, Brunning RD, Borowitz MJ, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009 Jul 30.##Scott Valastyan RAW. Tumor metastasis: molecular insights and evolving paradigms. Cell. 2011 Oct 14.##Erinn B Rankin J-MN, Amato J Giaccia. Hypoxia: Signaling the Metastatic Cascade Trends Cancer. 2016 Jun.##Wen Liu CJV, Amanda E Brinker, Kelsey R Hampton, Evi Lianidou, et al. Microenvironmental Influences on Metastasis Suppressor Expression and Function during a Metastatic Cell's Journey Cancer Microenviron. 2014 Dec.##Qiu-Luo Liu ML, Canhua Huang, Hai-Ning Chen, Zong-Guang Zhou. Epigenetic Regulation of Epithelial to Mesenchymal Transition in the Cancer Metastatic Cascade: Implications for Cancer Therapy Front Oncol. 2021 Apr 29.##Yifan Zhang SG, Jun Xia, Feng Liu. Hematopoietic Hierarchy - An Updated Roadmap. Trends Cell Biol. 2018 Dec.##Hui Cheng ZZ, Tao Cheng. New paradigms on hematopoietic stem cell differentiation. Protein Cell. 2020 Jan.##Suwei Gao YZ, Feng Liu. Revisiting the lineage contribution of hematopoietic stem and progenitor cells Development. 2023 Jul 15.##Amal Nazaraliyev ER, Catherine M Sawai. In-vivo differentiation of adult hematopoietic stem cells from a single-cell point of view Curr Opin Hematol. 2020 Jul.##Andrew E Whiteley TTP, Gaia Cantelli, Dorothy A Sipkins. Leukaemia: a model metastatic disease Nat Rev Cancer. 2021 Jul.##Trendowski. M. The inherent metastasis of leukaemia and its exploitation by sonodynamic therapy Crit Rev Oncol Hematol. 2015 May.##Wong RS CS. Leukaemic stem cells: drug resistance, metastasis and therapeutic implications. Malays J Pathol. 2012 Dec.##Deezagi Abdolkhaleg DS. Secreted tumor necrosis factor-alpha by human myeloid cells: a valuable parameter for evaluation of endotoxin contamination in vitro Immunopharmacol Immunotoxicol. 2009.##Patrick Stelmach AT. Leukemic stem cells and therapy resistance in acute myeloid leukemia Haematologica. 2023 Feb 1.##Craddock C QL, Goardon N, Freeman S, Siddique S, et al. Azacitidine fails to eradicate leukemic stem/progenitor cell populations in patients with acute myeloid leukemia and myelodysplasia. . Leukemia. 2013 Apr.##Nuno K AA, Koehnke T, Lareau C, Ediriwickrema A, et al. Convergent epigenetic evolution drives relapse in acute myeloid leukemia. Elife. 2024 Apr 22.##Maria Paprocka AB-P, Joanna Rossowska, Agnieszka Krawczenko, Danuta Duś, et al. MRP1 protein expression in leukemic stem cells as a negative prognostic marker in acute myeloid leukemia patients Eur J Haematol. 2017 Nov.##Jonathan M Burg JJG, Kenneth R Maksimchuk, Dewey G McCafferty. . Lysine-Specific Demethylase 1A (KDM1A/LSD1): Product Recognition and Kinetic Analysis of Full-Length Histones. Biochemistry. 2016 Mar 22.##Abhinav Dhall PMMS, Aurore M-F Delachat, Calvin J A Leonen, Beat Fierz, et al. Nucleosome Binding by the Lysine Specific Demethylase 1 (LSD1) Enzyme Enables Histone H3 Demethylation Biochemistry. 2020 Jul 14.##B Laurent YS. Expression, Purification, and Biochemical Analysis of the LSD1/KDM1A Histone Demethylase Methods Enzymol. 2016.##Kokura K SL, Fang J. In vitro histone demethylase assays. Methods Mol Biol. 2015.##Mosammaparast N SY. Reversal of histone methylation: biochemical and molecular mechanisms of histone demethylases. Annu Rev Biochem. 2010.##Vajari MK, Moradinasab S, Yousefi AM, Bashash D. Noncoding RNAs in diagnosis and prognosis of graft‐versus‐host disease (GVHD). Journal of Cellular Physiology. 2022;237(9):3480-95.##Jafari‐Raddani F, Davoodi‐Moghaddam Z, Yousefi AM, Ghaffari SH, Bashash D. An overview of long noncoding RNAs: Biology, functions, therapeutics, analysis methods, and bioinformatics tools. Cell Biochemistry and Function. 2022;40(8):800-25.##Mosammaparast N SY. miR-137 forms a regulatory loop with nuclear receptor TLX and LSD1 in neural stem cells. Annu Rev Biochem. 2010.##Divya Lenkala BL, Eric R Gamazon, Paul Geeleher, Hae Kyung Im, et al. The impact of microRNA expression on cellular proliferation Hum Genet. 2014 Jul.##Huang RS GE, Ziliak D, Wen Y, Im HK, et al. Population differences in microRNA expression and biological implications. RNA Biol. 2011 Jul-Aug.##Zhou J WW, Gao Z, Peng X, Chen X, et al. MicroRNA-155 promotes glioma cell proliferation via the regulation of MXI1. PLoS One. 2013 Dec 23.##Sheikhvatan M CS, Moazzami B. A Systematic Review and Bioinformatics Study on Genes and micro-RNAs Involving the Transformation of Endometriosis into Ovarian Cancer. Microrna. 2020.##GuoQiang Sun KA, Richard Stewart, Peng Ye, Su Yang, et al. Histone demethylase LSD1 regulates neural stem cell proliferation Mol Cell Biol. 2010 Apr.##Sun G YR, Evans RM, Shi Y. Orphan nuclear receptor TLX recruits histone deacetylases to repress transcription and regulate neural stem cell proliferation. Proc Natl Acad Sci U S A. 2007 Sep 25##Zheng YC YB, Jiang GZ, Feng XJ, He PX, et al. Irreversible LSD1 Inhibitors: Application of Tranylcypromine and Its Derivatives in Cancer Treatment. Curr Top Med Chem. 2016.##Anna Guarini MM, Simona Tavolaro, Emanuele Bellacchio, Monia Magliozzi, et al. ATM gene alterations in chronic lymphocytic leukemia patients induce a distinct gene expression profile and predict disease progression Haematologica. 2012 Jan.##Anna Skowronska AP, Gulshanara Ahmed, Ceri Oldreive, Zadie Davis, et al. Biallelic ATM inactivation significantly reduces survival in patients treated on the United Kingdom Leukemia Research Fund Chronic Lymphocytic Leukemia 4 trial J Clin Oncol. 2012 Dec 20.##Belinda Austen AS, Claire Baker, Judith E Powell, Anne Gardiner, et al. Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion J Clin Oncol. 2007 Dec 1.##Skowronska A AB, Powell JE, Weston V, Oscier DG, et al. ATM germline heterozygosity does not play a role in chronic lymphocytic leukemia initiation but influences rapid disease progression through loss of the remaining ATM allele. Haematologica. 2012 Jan.##Ke Lin JA, Gillian G Johnson, Anthony Carter, Melanie Oates, et al. Functional analysis of the ATM-p53-p21 pathway in the LRF CLL4 trial: blockade at the level of p21 is associated with short response duration Clin Cancer Res. 2012 Aug 1.##Thorsten Zenz AB, Hartmut Döhner, Stephan Stilgenbauer. Chronic lymphocytic leukemia and treatment resistance in cancer: the role of the p53 pathway Cell Cycle. 2008 Dec 15.##Zenz T MJ, Edelmann J, Sarno A, Hoth P, et al. Treatment resistance in chronic lymphocytic leukemia: the role of the p53 pathway. Leuk Lymphoma. 2009 Mar.##Zenz T HS, Denzel T, Mohr J, Winkler D, et al. Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial. Blood. 2009 Sep 24.##Elaine Willmore AS, Evan A Mulligan, G. Ahmed,Sarah Elliott, et al. ATM Mutant Chronic Lymphocytic Leukaemia Cells are Chemosensitized by Inhibition of DNA-Dependent Protein Kinase Blood. 2010.##Gero Knittel PL, Hans C Reinhardt. Targeting ATM-deficient CLL through interference with DNA repair pathways. Front Genet. 2015 Jun 10.##Kastan MB LD. The many substrates and functions of ATM. Nat Rev Mol Cell Biol. 2000.##Uziel T SK, Platzer M, Ziv Y, Helbitz T, et al. Genomic organization of the ATM gene. Genomics. 1996.##Y-S Kim B-SP, H-S Baek, H-M Kang, J-M Oh, et al. Metformin activates AMPK and mTOR to Inhibit RANKL-stimulated osteoclast formation. Eur Rev Med Pharmacol Sci. 2023 Sep.##Zamanian MY GM, Yumashev A, Hjazi A, Toama MA, et al. Effects of metformin on cancers in experimental and clinical studies: Focusing on autophagy and AMPK/mTOR signaling pathways. Cell Biochem Funct. 2024 Jun.##Andreas Janzer NJG, Karina N Gonzalez-Herrera, John M Asara, Marcia C Haigis, et al. Metformin and phenformin deplete tricarboxylic acid cycle and glycolytic intermediates during cell transformation and NTPs in cancer stem cells. Proc Natl Acad Sci U S A. 2014 Jul 7.##Célia Rosilio NL, Marielle Nebout, Véronique Imbert, Thijs Hagenbeek, et al. The metabolic perturbators metformin, phenformin and AICAR interfere with the growth and survival of murine PTEN-deficient T cell lymphomas and human T-ALL/T-LL cancer cells Cancer Lett. 2013 Aug.##Huypens P QE, Pipeleers D, Van de Casteele M. Metformin reduces adiponectin protein expression and release in 3T3-L1 adipocytes involving activation of AMP activated protein kinase. Eur J Pharmacol. 2005 Aug 22.##Singh-Makkar S PK, Hathaway D 3rd, Paul T, Youssef P. Multidimensional mechanisms of metformin in cancer treatment. Tumori. 2022 Apr.##S Scotland ES, N Skuli, F de Toni, H Boutzen, E Micklow, et al. Mitochondrial energetic and AKT status mediate metabolic effects and apoptosis of metformin in human leukemic cells Leukemia. 2013 Nov.##Chen-Song Zhang ML, Teng Ma, Yue Zong, Jiwen Cui, et al. Metformin Activates AMPK through the Lysosomal Pathway Cell Metab. 2016 Oct 11.##B Chaube MKB. AMPK, a key regulator of metabolic/energy homeostasis and mitochondrial biogenesis in cancer cells. Cell Death Dis. 2016 Jan.##Yun Chau Long JRZ. AMP-activated protein kinase signaling in metabolic regulation. J Clin Invest. 2006 Jul 3.##Emilia Amengual-Cladera PMM-B, Andrea Morán-Costoya, Jorge Sastre-Serra, Daniel Gabriel Pons, et al. Metformin: From Diabetes to Cancer-Unveiling Molecular Mechanisms and Therapeutic Strategies Biology (Basel). 2024.##Nerea Allende-Vega JMB, Paolo Falvo, Catherine Alexia, Michael Constantinides, et al. Metformin sensitizes leukemic cells to cytotoxic lymphocytes by increasing expression of intercellular adhesion molecule-1 (ICAM-1). nature(scientific reports). 25 January 2022.##N Yagi KY, K Amano, M Nagata, K Tsukamoto, et al. Expression of intercellular adhesion molecule 1 on pancreatic beta-cells accelerates beta-cell destruction by cytotoxic T-cells in murine autoimmune diabetes Comparative Study Diabetes. 1995 Jul.##P Wang FV, S L Li, M Patarroyo, E Klein. Functional characteristics of the intercellular adhesion molecule-1 (CD54) expressed on cytotoxic human blood lymphocytes Cell Immunol. 1990 Dec.##Yong Yi WZ, Jianqiao Yi, Zhi-Xiong Xiao. . Role of p53 Family Proteins in Metformin Anti-Cancer Activities. J Cancer. 2019 May 27.##Hollstein M SD, Vogelstein B. p53 mutations in human cancers. Science. 1991.##E. D. The most popular genes in the human genome. Nature. 2017.##Ebrahim Miri-Moghaddam AD, Zahra Sohaila Soheili, Parvin Shariati. Apoptosis and reduced cell proliferation of HL-60 cell line caused by human telomerase reverse transcriptase inhibition by siRNA. Acta Haematol. 2010.##Gao Yi ZH, Xinke Zhou, Lewu Xian, Taize Yuan, et al. Low concentration of metformin induces a p53-dependent senescence in hepatoma cells via activation of the AMPK pathway Int J Oncol. 2013 Nov.##Heather A Hirsch DI, Philip N Tsichlis, Kevin Struhl. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission Cancer Res. 2009 Oct 1.##Mohsen Hosseini VV, Ali Chegini, Angelica Varesi, Severine Cathelin, et al. Metformin reduces the competitive advantage of Dnmt3aR878H HSPCs. Nature. 2025 Jun.##Mohsen Hosseini VV, Ali Chegini, Angelica Varesi, Severine Cathelin, et al. . Metformin reduces the clonal fitness of Dnmt3a R878H hematopoietic stem and progenitor cells by reversing their aberrant metabolic and epigenetic state. Res Sq. 2024 Feb 6.##Parisa Dana NHR, Parichehreh Yaghmaei,Zahra Hajebrahimi. ffects of empagliflozin on the expression of kisspeptin gene and reproductive system function in streptozotocin-induced diabetic male rats. Front Endocrinol. 21 November 2022.##Parisa Dana NHR, Parichehreh Yaghmaei, Zahra Haj Ebrahimi. Effects of Empagliflozin on Sexual Function, Testicular Histology and Biochemical Parameters in Young and Middle-Aged Diabetic Rats of Type2. Iranian Journal of Diabetes and Metabolism. 2021.## ##

The Role of Artificial Intelligence in Shaping the Future of Hematological Diagnosis and Treatment 2 2 Hematological disorders continue to pose significant challenges in clinical practice due to their complexity and potential for severe outcomes. This review provides a comprehensive overview of the role of Artificial Intelligence (AI) in enhancing the diagnosis and treatment of these conditions. Drawing on 177 studies published between 2012 and 2025 from PubMed and Google Scholar, the review examines fundamental concepts of AI and machine learning, their applications in diagnostic and therapeutic processes, and the challenges and limitations associated with their clinical implementation. The findings highlight the potential of AI to improve diagnostic accuracy, optimize treatment strategies, and support decision-making in hematology. By synthesizing current knowledge, this study underscores the importance of integrating AI into research and clinical practice and offers insights into future directions for advancing patient care in hematological disorders. 46 61 2025/07/42025/07/142025/08/192025/07/242025/07/172025/08/10 1404/5/19 2025/09/242025/09/112025/09/112025/09/112025/09/172025/09/25 1404/7/3 Zahra Haghshenas Zahra Haghshenas School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Hassan Shokri Garjan Hassan Shokri Garjan Department of Medical Informatics, School of Allied Medical Science, Urmia University of Medical Science, Urmia, Iran. Atefeh Moghassem Atefeh Moghassem Laboratory Hematology and Blood Bank Department, School of Allied Medical Science, Shahid Beheshti University of Medical Science, Tehran, Iran. Pooya Vahedi Pooya Vahedi School of Medicine, Shahid Beheshti University of Medical Science, Tehran, Iran. Yasmin Tabatabavakili Yasmin Tabatabavakili School of Nursing and Midwifery, Shahid Beheshti University of Medical Science, Tehran, Iran. Diana Hosseinzadeh Diana Hosseinzadeh Third faculty of medicine, Charles University, Prague, Czech Republic. Goli Asgari Goli Asgari Proteomics Research Center, Faculty of Paramedical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Elham Nazari Elham Nazari Proteomics Research Center, Faculty of Paramedical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Elham.Nazari@sbmu.ac.ir Tahmine Aldaghi Tahmine Aldaghi Institute of Biophysics and Informatics, First Faculty of Medicine, Charles University, Prague, Czech Republic tahmineh1989@gmail.com Artificial intelligence Machine learning Hematological disorders Pan T, Zhang J, Wang X, Song Y. Global burden and trends of hematologic malignancies based on Global Cancer Observatory 2022 and Global Burden of Disease 2021. Exp Hematol Oncol. 2025;14(1):98.##Sun D, Chen W, He J, He Y, Jiang H, Jiang H, et al. A novel method for screening malignant hematological diseases by constructing an optimal machine learning model based on blood cell parameters. BMC Medical Informatics and Decision Making. 2025;25(1).##Collaborators GBDA. Prevalence, years lived with disability, and trends in anaemia burden by severity and cause, 1990-2021: findings from the Global Burden of Disease Study 2021. Lancet Haematol. 2023;10(9):e713-e34.##Liao H, Zhang F, Chen F, Li Y, Sun Y, Sloboda DD, et al. Application of artificial intelligence in laboratory hematology: Advances, challenges, and prospects. Acta Pharmaceutica Sinica B. 2025.##Isa A, Yusoff NM, Hamdani HY, Nazman HNM, Alhawamdeh M, Abeden Z, et al. Application of artificial intelligence in the diagnosis of haematological disorders. Biomedical Research and Therapy. 2024;11(12):6989-7002.##Wang S-X, Huang Z-F, Li J, Wu Y, Du J, Li T. Optimization of diagnosis and treatment of hematological diseases via artificial intelligence. Frontiers in Medicine. 2024;11.##El Alaoui Y, Elomri A, Qaraqe M, Padmanabhan R, Yasin Taha R, El Omri H, et al. A Review of Artificial Intelligence Applications in Hematology Management: Current Practices and Future Prospects. Journal of Medical Internet Research. 2022;24(7).##Ekpe N, Odii A, Adene G, Aguzu L. Applications of Artificial Intelligence and Machine Learning in Clinical Practice. 2025;3:1-15.##T S, B GJ. From algorithm to applications: Artificial intelligence - A future prospective in medicine. Sri Ramachandra Journal of Health Sciences. 2025;4:44-52.##Amisha, Malik P, Pathania M, Rathaur VK. Overview of artificial intelligence in medicine. J Family Med Prim Care. 2019;8(7):2328-31.##Srivastava R. Applications of Artificial Intelligence in Medicine. Exploratory Research and Hypothesis in Medicine. 2023;9(2):138-46.##Eskandar K. Artificial Intelligence in Healthcare: Explore the Applications of AI in Various Medical Domains, Such as Medical Imaging, Diagnosis, Drug Discovery, and Patient Care. 2023;1:37-53.##Walter W, Pohlkamp C, Meggendorfer M, Nadarajah N, Kern W, Haferlach C, et al. Artificial intelligence in hematological diagnostics: Game changer or gadget? Blood Reviews. 2023;58.##Alowais SA, Alghamdi SS, Alsuhebany N, Alqahtani T, Alshaya AI, Almohareb SN, et al. Revolutionizing healthcare: the role of artificial intelligence in clinical practice. BMC Medical Education. 2023;23(1).##Chimmula VKR, Zhang L. Time series forecasting of COVID-19 transmission in Canada using LSTM networks. Chaos Solitons Fractals. 2020;135:109864.##Xu Y, Liu X, Cao X, Huang C, Liu E, Qian S, et al. Artificial intelligence: A powerful paradigm for scientific research. Innovation (Camb). 2021;2(4):100179.##Akanksha M. A Comprehensive Review of Artificial Intelligence and Machine Learning : Concepts, Trends, and Applications. International Journal of Scientific Research in Science and Technology. 2024;11(5):126-42.##Rojas-Carabali W, Agrawal R, Gutierrez-Sinisterra L, Baxter SL, Cifuentes-González C, Wei YC, et al. Natural Language Processing in medicine and ophthalmology: A review for the 21st-century clinician. Asia Pac J Ophthalmol (Phila). 2024;13(4):100084.##Furizal F, Ma'arif A, Rifaldi D. Application of Machine Learning in Healthcare and Medicine: A Review. Journal of Robotics and Control (JRC). 2023;4(5):621-31.##Rashidi HH, Pantanowitz J, Hanna MG, Tafti AP, Sanghani P, Buchinsky A, et al. Introduction to Artificial Intelligence and Machine Learning in Pathology and Medicine: Generative and Nongenerative Artificial Intelligence Basics. Modern Pathology. 2025;38(4).##Taye MM. Understanding of Machine Learning with Deep Learning: Architectures, Workflow, Applications and Future Directions. Computers. 2023;12(5):91.##Kufel J, Bargieł-Łączek K, Kocot S, Koźlik M, Bartnikowska W, Janik M, et al. What Is Machine Learning, Artificial Neural Networks and Deep Learning?-Examples of Practical Applications in Medicine. Diagnostics. 2023;13(15).##Bali J, Bali O. Artificial Intelligence Applications in Medicine: A Rapid Overview of Current Paradigms. EMJ Innovations. 2020:73-81.##Trezza A, Visibelli A, Roncaglia B, Spiga O, Santucci A. Unsupervised Learning in Precision Medicine: Unlocking Personalized Healthcare through AI. Applied Sciences. 2024;14(20):9305.##Tettey-Engmann F, Parupelli SK, Bauer SR, Bhattarai N, Desai S. Advances in Artificial Intelligence-Based Medical Devices for Healthcare Applications. Biomedical Materials & Devices. 2025.##Woodman RJ, Mangoni AA. A comprehensive review of machine learning algorithms and their application in geriatric medicine: present and future. Aging Clinical and Experimental Research. 2023;35(11):2363-97.##Rieu Z, Kim J, Kim RE, Lee M, Lee MK, Oh SW, et al. Semi-Supervised Learning in Medical MRI Segmentation: Brain Tissue with White Matter Hyperintensity Segmentation Using FLAIR MRI. Brain Sciences. 2021;11(6):720.##Sarker IH. AI-Based Modeling: Techniques, Applications and Research Issues Towards Automation, Intelligent and Smart Systems. SN Comput Sci. 2022;3(2):158.##Anzabi Zadeh S, Street WN, Thomas BW. Optimizing warfarin dosing using deep reinforcement learning. J Biomed Inform. 2023;137:104267.##Kaul V, Enslin S, Gross SA. History of artificial intelligence in medicine. Gastrointestinal Endoscopy. 2020;92(4):807-12.##Grzybowski A, Brona P, Lim G, Ruamviboonsuk P, Tan GSW, Abramoff M, et al. Artificial intelligence for diabetic retinopathy screening: a review. Eye (Lond). 2020;34(3):451-60.##https://doi.org/10.1038/s41433-019-0566-0##Miotto R, Wang F, Wang S, Jiang X, Dudley JT. Deep learning for healthcare: review, opportunities and challenges. Brief Bioinform. 2018;19(6):1236-46.##Chakraborty C, Bhattacharya M, Pal S, Lee S-S. From machine learning to deep learning: Advances of the recent data-driven paradigm shift in medicine and healthcare. Current Research in Biotechnology. 2024;7.##Prasoon A, Petersen K, Igel C, Lauze F, Dam E, Nielsen M. Deep feature learning for knee cartilage segmentation using a triplanar convolutional neural network. Med Image Comput Comput Assist Interv. 2013;16(Pt 2):246-53.##Chen R, Stewart WF, Sun J, Ng K, Yan X. Recurrent Neural Networks for Early Detection of Heart Failure From Longitudinal Electronic Health Record Data. Circulation: Cardiovascular Quality and Outcomes. 2019;12(10).##Choi E, Schuetz A, Stewart WF, Sun J. Using recurrent neural network models for early detection of heart failure onset. J Am Med Inform Assoc. 2017;24(2):361-70.##Si Y, Du J, Li Z, Jiang X, Miller T, Wang F, et al. Deep representation learning of patient data from Electronic Health Records (EHR): A systematic review. Journal of Biomedical Informatics. 2021;115:103671.##Joshi D, Singh B, Kalonia S, Kaushik AK, Goyal N, Maggu S, editors. Predictive Modeling of Cardiovascular Disease Using Feedforward Neural Networks. Proceedings of International Conference on Paradigms of Communication, Computing and Data Analytics; 2025 2025//; Singapore: Springer Nature Singapore.##Tran T, Nguyen TD, Phung D, Venkatesh S. Learning vector representation of medical objects via EMR-driven nonnegative restricted Boltzmann machines (eNRBM). J Biomed Inform. 2015;54:96-105.##Fakoor R, Ladhak F, Nazi A, Huber M. Using deep learning to enhance cancer diagnosis and classification2013.##Reis TC. Deep learning in oncology: Transforming cancer diagnosis, prognosis, and treatment. Emerging Trends in Drugs, Addictions, and Health. 2025;5.##Ucucu S, Azik F. Artificial intelligence-driven diagnosis of beta-thalassemia minor & iron deficiency anemia using machine learning models. J Med Biochem. 2024;43(1):11-8.##Kitaw B, Asefa C, Legese F. Leveraging machine learning models for anemia severity detection among pregnant women following ANC: Ethiopian context. BMC Public Health. 2024;24(1):3500.##Vohra R, Hussain A, Dudyala AK, Pahareeya J, Khan W. Multi-class classification algorithms for the diagnosis of anemia in an outpatient clinical setting. PLoS One. 2022;17(7):e0269685.##Mansour M, Donmez TB, Kutlu M, Mahmud S. Non-invasive detection of anemia using lip mucosa images transfer learning convolutional neural networks. Front Big Data. 2023;6:1291329.##Ramzan M, Sheng J, Saeed MU, Wang B, Duraihem FZ. Revolutionizing anemia detection: integrative machine learning models and advanced attention mechanisms. Vis Comput Ind Biomed Art. 2024;7(1):18.##Appiahene P, Asare JW, Donkoh ET, Dimauro G, Maglietta R. Detection of iron deficiency anemia by medical images: a comparative study of machine learning algorithms. BioData Min. 2023;16(1):2.##Sehar N, Krishnamoorthi N, Vinoth Kumar C. Deep Learning Model-Based Detection of Anemia from Conjunctiva Images. Healthc Inform Res. 2025;31(1):57-65.##Saputra DCE, Sunat K, Ratnaningsih T. A New Artificial Intelligence Approach Using Extreme Learning Machine as the Potentially Effective Model to Predict and Analyze the Diagnosis of Anemia. Healthcare (Basel). 2023;11(5).##Tyas DA, Hartati S, Harjoko A, Ratnaningsih T. Morphological, Texture, and Color Feature Analysis for Erythrocyte Classification in Thalassemia Cases. IEEE Access. 2020;8:69849-60.##Aszhari FR, Rustam Z, Subroto F, Semendawai AS. Classification of thalassemia data using random forest algorithm. 2020;1490(1).##Eckardt JN, Middeke JM, Riechert S, Schmittmann T, Sulaiman AS, Kramer M, et al. Deep learning detects acute myeloid leukemia and predicts NPM1 mutation status from bone marrow smears. Leukemia. 2022;36(1):111-8.##Nazari E, Farzin AH, Aghemiri M, Avan A, Tara M, Tabesh H. Deep Learning for Acute Myeloid Leukemia Diagnosis. J Med Life. 2020;13(3):382-7.##Sampathila N, Chadaga K, Goswami N, Chadaga RP, Pandya M, Prabhu S, et al. Customized Deep Learning Classifier for Detection of Acute Lymphoblastic Leukemia Using Blood Smear Images. Healthcare (Basel). 2022;10(10).##Rezayi S, Mohammadzadeh N, Bouraghi H, Saeedi S, Mohammadpour A. Timely Diagnosis of Acute Lymphoblastic Leukemia Using Artificial Intelligence-Oriented Deep Learning Methods. Comput Intell Neurosci. 2021;2021:5478157.##El Houby EMF. Acute lymphoblastic leukemia diagnosis using machine learning techniques based on selected features. Sci Rep. 2025;15(1):28056.##Eckardt JN, Schmittmann T, Riechert S, Kramer M, Sulaiman AS, Sockel K, et al. Deep learning identifies Acute Promyelocytic Leukemia in bone marrow smears. BMC Cancer. 2022;22(1):201.##Manescu P, Narayanan P, Bendkowski C, Elmi M, Claveau R, Pawar V, et al. Detection of acute promyelocytic leukemia in peripheral blood and bone marrow with annotation-free deep learning. Sci Rep. 2023;13(1):2562.##Sidhom JW, Siddarthan IJ, Lai BS, Luo A, Hambley BC, Bynum J, et al. Deep learning for diagnosis of acute promyelocytic leukemia via recognition of genomically imprinted morphologic features. NPJ Precis Oncol. 2021;5(1):38.##Shaabanpour Aghamaleki F, Mollashahi B, Nosrati M, Moradi A, Sheikhpour M, Movafagh A. Application of an Artificial Neural Network in the Diagnosis of Chronic Lymphocytic Leukemia. Cureus. 2019;11(2):e4004.##Huang F, Guang P, Li F, Liu X, Zhang W, Huang W. AML, ALL, and CML classification and diagnosis based on bone marrow cell morphology combined with convolutional neural network: A STARD compliant diagnosis research. Medicine (Baltimore). 2020;99(45):e23154.##Achi HE, Belousova T, Chen L, Wahed A, Wang I, Hu Z, et al. Automated Diagnosis of Lymphoma with Digital Pathology Images Using Deep Learning. 2018.##Li D, Bledsoe JR, Zeng Y, Liu W, Hu Y, Bi K, et al. A deep learning diagnostic platform for diffuse large B-cell lymphoma with high accuracy across multiple hospitals. Nat Commun. 2020;11(1):6004.##https://doi.org/10.1038/s41467-024-49660-9##Zhang Y, Deng Y, Zou Q, Jing B, Cai P, Tian X, et al. Artificial intelligence for diagnosis and prognosis prediction of natural killer/T cell lymphoma using magnetic resonance imaging. Cell Rep Med. 2024;5(5):101551.##Kong H, Zhu H, Zheng X, Jiang M, Chen L, Lan L, et al. Machine Learning Models for the Diagnosis and Prognosis Prediction of High-Grade B-Cell Lymphoma. Front Immunol. 2022;13:919012.##Delrue C, Hofmans M, Van Dorpe J, Van der Linden M, Van Gaever Z, Kerre T, et al. Innovative label-free lymphoma diagnosis using infrared spectroscopy and machine learning on tissue sections. Commun Biol. 2024;7(1):1419.##Peng T, Liu L, Liu F, Ding L, Liu J, Zhou H, et al. Machine learning-based infection prediction model for newly diagnosed multiple myeloma patients. Front Neuroinform. 2022;16:1063610.##Yan W, Shi H, He T, Chen J, Wang C, Liao A, et al. Employment of Artificial Intelligence Based on Routine Laboratory Results for the Early Diagnosis of Multiple Myeloma. Front Oncol. 2021;11:608191.##Chen X, Zhang Y, Li X, Yang Z, Liu A, Yu X. Diagnosis and staging of multiple myeloma using serum-based laser-induced breakdown spectroscopy combined with machine learning methods. Biomed Opt Express. 2021;12(6):3584-96.##Wang M, Dong C, Gao Y, Li J, Han M, Wang L. A Deep Learning Model for the Automatic Recognition of Aplastic Anemia, Myelodysplastic Syndromes, and Acute Myeloid Leukemia Based on Bone Marrow Smear. Front Oncol. 2022;12:844978.##Nagao A, Inagaki Y, Nogami K, Yamasaki N, Iwasaki F, Liu Y, et al. Artificial intelligence-assisted ultrasound imaging in hemophilia: research, development, and evaluation of hemarthrosis and synovitis detection. Res Pract Thromb Haemost. 2024;8(4):102439.##Tyrrell PN, Alvarez-Roman MT, Bakeer N, Brand-Staufer B, Jimenez-Yuste V, Kras S, et al. Utilizing artificial intelligence for the detection of hemarthrosis in hemophilia using point-of-care ultrasonography. Res Pract Thromb Haemost. 2024;8(8):102602.##Ferreira MV, Nogueira T, Rios RA, Lopes TJS. A graph-based machine learning framework identifies critical properties of FVIII that lead to hemophilia A. Front Bioinform. 2023;3:1152039.##Bibi N, Sikandar M, Ud Din I, Almogren A, Ali S. IoMT-Based Automated Detection and Classification of Leukemia Using Deep Learning. J Healthc Eng. 2020;2020:6648574.##Dasariraju S, Huo M, McCalla S. Detection and Classification of Immature Leukocytes for Diagnosis of Acute Myeloid Leukemia Using Random Forest Algorithm. Bioengineering (Basel). 2020;7(4).##Venezian Povoa L, Ribeiro CHC, Silva ITd. Machine learning predicts treatment sensitivity in multiple myeloma based on molecular and clinical information coupled with drug response. PLoS One. 2021;16(7):e0254596.##Ferle M, Grieb N, Kreuz M, Ader J, Goldschmidt H, Mai EK, et al. Predicting progression events in multiple myeloma from routine blood work. NPJ digital medicine. 2025;8(1):231.##https://doi.org/10.1038/s41746-025-01719-7##Karathanasis N, Spyrou GM. Machine Learning Models for Predicting Multiple Myeloma Staging and MGUS Progression Using Gene Expression Data. bioRxiv. 2024:2024.11. 12.623149.##Qin Y. Machine learning-based biomarker screening for acute myeloid leukemia prognosis and therapy from diverse cell-death patterns. Scientific Reports. 2024;14:17874.##Kosvyra Α, Karadimitris Α, Papaioannou Μ, Chouvarda I. Machine learning and integrative multi-omics network analysis for survival prediction in acute myeloid leukemia. Computers in Biology and Medicine. 2024;178:108735.##Mitra A, Kumar A, Amdare NP, Pathak R. Current landscape of cancer immunotherapy: harnessing the immune arsenal to overcome immune evasion. Biology. 2024;13(5):307.##Zhang Y. Artificial intelligence for diagnosis and prognosis prediction of natural killer/T cell lymphoma using magnetic resonance imaging. Cell Reports Medicine. 2024;5:101551.##Naji H, Hahn P, Pisula JI, Ugliano S, Simon A, Büttner R, et al. Deep learning-based interpretable prediction of recurrence of diffuse large B-cell lymphoma. BJC Reports. 2025;3(1):34.##Ahmad W, Shahzad AR, Amin MA, Bangyal WH, Alahmadi TJ, Khan SH. Machine learning driven dashboard for chronic myeloid leukemia prediction using protein sequences. PLoS One. 2025;20(6):e0321761.##Hauser RG. A Machine Learning Model to Successfully Predict Future Diagnosis of Chronic Myelogenous Leukemia With Retrospective Electronic Health Records Data. Am J Clin Pathol. 2021;156:1142-8.##Ram M. Application of artificial intelligence in chronic myeloid leukemia (CML) disease prediction and management: a scoping review. BMC Cancer. 2024;24:1026.##Ai D, Cui C, Tang Y, Wang Y, Zhang N, Zhang C, et al. Machine learning model for predicting physical activity related bleeding risk in Chinese boys with haemophilia A. Thrombosis Research. 2023;232:43-53.##Allegra A, Tonacci A, Sciaccotta R, Genovese S, Musolino C, Pioggia G, et al. Machine learning and deep learning applications in multiple myeloma diagnosis, prognosis, and treatment selection. Cancers. 2022;14(3):606.##Abdel-Rehim A, Orhobor O, Griffiths G, Soldatova L, King RD. Establishing predictive machine learning models for drug responses in patient derived cell culture. npj Precision Oncology. 2025;9(1):180.##Azarkhish I. Artificial Intelligence Models for Predicting Iron Deficiency Anemia and Iron Serum Level Based on Accessible Laboratory Data. J Med Syst. 2012;36:2057-61.##Rezayi S. Timely Diagnosis of Acute Lymphoblastic Leukemia Using Artificial Intelligence-Oriented Deep Learning Methods. Computational Intelligence and Neuroscience. 2021;2021:5478157.##Cheng ZJ. Artificial intelligence reveals the predictions of hematological indexes in children with acute leukemia. BMC Cancer. 2024;24:993.##Alhajahjeh A, Nazha A. Unlocking the Potential of Artificial Intelligence in Acute Myeloid Leukemia and Myelodysplastic Syndromes. Current Hematologic Malignancy Reports. 2024;19:9-17.##Azarkhish I, Raoufy MR, Gharibzadeh S. Artificial intelligence models for predicting iron deficiency anemia and iron serum level based on accessible laboratory data. Journal of medical systems. 2012;36(3):2057-61.##Wang V, Gauthier M, Decot V, Reppel L, Bensoussan D. Systematic review on CAR-T cell clinical trials up to 2022: academic center input. Cancers. 2023;15(4):1003.##Qu Y, Huang K, Yin M, Zhan K, Liu D, Yin D, et al. CRISPR-GPT for agentic automation of gene-editing experiments. Nature Biomedical Engineering. 2025:1-14.##Abbaszadeh A, Shahlai A. Artificial Intelligence for CRISPR Guide RNA Design: Explainable Models and Off-Target Safety. arXiv preprint arXiv:250820130. 2025.##Cai S. Artificial intelligence for improving sickle cell retinopathy diagnosis and management. Eye. 2021;35:2675-84.##Boretti A. The transformative potential of AI-driven CRISPR-Cas9 genome editing to enhance CAR T-cell therapy. Computers in biology and medicine. 2024;182:109137.##Dermawan D, Alotaiq N. From Lab to Clinic: How Artificial Intelligence (AI) Is Reshaping Drug Discovery Timelines and Industry Outcomes. Pharmaceuticals. 2025;18(7):981.##Chihara D, Kane MJ, Flowers CR, Hobbs BP. Utilizing Synthetic Individual Patient Level Cohorts from Machine Learning on Clinical Trials to Define Endpoints for Bispecific Trials in Large B-Cell Lymphoma. Blood. 2024;144:4462.##D'Amico S. Synthetic Data Generation by Artificial Intelligence to Accelerate Research and Precision Medicine in Hematology. JCO Clinical Cancer Informatics. 2023;7:e2300021.##Li L, Peng M, Zou Y, Li Y, Qiao P. The promise and limitations of artificial intelligence in CTPA-based pulmonary embolism detection. Frontiers in Medicine. 2025;Volume 12 - 2025.##Obeagu EI. Revolutionizing hematological disorder diagnosis: unraveling the role of artificial intelligence. Annals of Medicine and Surgery. 2025;87(6):3445-57.##Karako K. Artificial intelligence applications in rare and intractable diseases: Advances, challenges, and future directions. Intractable Rare Dis Res. 2025;14(2):88-92.##Wang J. Deep Learning in Hematology: From Molecules to Patients. Clin Hematol Int. 2024;6(4):19-42.##Yang Y, Sun K, Gao Y, Wang K, Yu G. Preparing Data for Artificial Intelligence in Pathology with Clinical-Grade Performance. Diagnostics. 2023;13(19):3115.##Meng J, Wu M, Shi F, Xie Y, Wang H, Guo Y. Medical laboratory data-based models: opportunities, obstacles, and solutions. Journal of Translational Medicine. 2025;23(1):823.##Kang C, Lee C, Song H, Ma M, Pereira S, editors. Variability matters: Evaluating inter-rater variability in histopathology for robust cell detection. European Conference on Computer Vision; 2022: Springer.##Marrón-Esquivel JM, Duran-Lopez L, Linares-Barranco A, Dominguez-Morales JP. A comparative study of the inter-observer variability on Gleason grading against Deep Learning-based approaches for prostate cancer. Comput Biol Med. 2023;159:106856.##Cazzaniga G, Del Carro F, Eccher A, Becker JU, Gambaro G, Rossi M, et al. Improving the Annotation Process in Computational Pathology: A Pilot Study with Manual and Semi-automated Approaches on Consumer and Medical Grade Devices. J Imaging Inform Med. 2025;38(2):1112-9.##Wilm F, Bertram CA, Marzahl C, Bartel A, Donovan TA, Assenmacher C-A, et al., editors. Influence of inter-annotator variability on automatic mitotic figure assessment. Bildverarbeitung für die Medizin 2021: Proceedings, German Workshop on Medical Image Computing, Regensburg, March 7-9, 2021; 2021: Springer.##Dehkharghanian T, Mu Y, Tizhoosh HR, Campbell CJ. Applied machine learning in hematopathology. International Journal of Laboratory Hematology. 2023;45:87-94.##Li N, Lewin A, Ning S, Waito M, Zeller MP, Tinmouth A, et al. Privacy-preserving federated data access and federated learning: Improved data sharing and AI model development in transfusion medicine. Transfusion. 2025;65(1):22-8.##https://doi.org/10.1111/trf.16741##Asti G, D'Amico S, Carota L, Piscia D, Casadei F, Merleau NSC, et al. An Artificial Intelligence-Based Federated Learning Platform to Boost Precision Medicine in Rare Hematological Diseases: An Initiative By GenoMed4all and Synthema Consortia. Blood. 2024;144:4989.##Schouten D, Nicoletti G, Dille B, Chia C, Vendittelli P, Schuurmans M, et al. Navigating the landscape of multimodal AI in medicine: a scoping review on technical challenges and clinical applications. Medical Image Analysis. 2025:103621.##Reinecke D, Maroouf N, Smith A, Alber D, Markert J, Goff NK, et al. Fast intraoperative detection of primary CNS lymphoma and differentiation from common CNS tumors using stimulated Raman histology and deep learning. medRxiv. 2024.##Cheng FM, Lo SC, Lin CC, Lo WJ, Chien SY, Sun TH, et al. Deep learning assists in acute leukemia detection and cell classification via flow cytometry using the acute leukemia orientation tube. Sci Rep. 2024;14(1):8350.##Salama ME, Otteson GE, Camp JJ, Seheult JN, Jevremovic D, Holmes DR, 3rd, et al. Artificial Intelligence Enhances Diagnostic Flow Cytometry Workflow in the Detection of Minimal Residual Disease of Chronic Lymphocytic Leukemia. Cancers (Basel). 2022;14(10).##Asar TO, Ragab M. Leukemia detection and classification using computer-aided diagnosis system with falcon optimization algorithm and deep learning. Sci Rep. 2024;14(1):21755.##Pan L, Li L, Qiu Y, Ling X, Wang C, Wu Z, et al. A novel discriminant algorithm for differential diagnosis of mild to moderate thalassemia and iron deficiency anemia. Medicine (Baltimore). 2024;103(20):e38205.##Lyons J, Desai V, Xu Y, Ridgeway G, Finkle W, Solari P, et al. Development and Validation of an Algorithm for Identifying Patients with Hemophilia A in an Administrative Claims Database. Value Health. 2018;21(9):1098-103.##Lei Y, Wei H, Gao X. High temporal resolution prediction of mortality risk for single AML patient via deep learning. iScience. 2024;27(8):110458.##Didi I, Alliot JM, Dumas PY, Vergez F, Tavitian S, Largeaud L, et al. Artificial intelligence-based prediction models for acute myeloid leukemia using real-life data: A DATAML registry study. Leuk Res. 2024;136:107437.##Zhao S, Wang J, Jin C, Zhang X, Xue C, Zhou R, et al. Stacking Ensemble Learning-Based [18F]FDG PET Radiomics for Outcome Prediction in Diffuse Large B-Cell Lymphoma. Journal of Nuclear Medicine. 2023;64(10):1603-9.##Jardim LL, Schieber TA, Santana MP, Cerqueira MH, Lorenzato CS, Franco VKB, et al. Prediction of inhibitor development in previously untreated and minimally treated children with severe and moderately severe hemophilia A using a machine-learning network. J Thromb Haemost. 2024;22(9):2426-37.##Khosla E, Ramesh D. Phase classification of chronic myeloid leukemia using convolution neural networks2018. 1-6 p.##Sasaki K, Jabbour EJ, Ravandi F, Konopleva M, Borthakur G, Wierda WG, et al. The LEukemia Artificial Intelligence Program (LEAP) in chronic myeloid leukemia in chronic phase: A model to improve patient outcomes. Am J Hematol. 2021;96(2):241-50.##Mehrbakhsh Z, Hassanzadeh R, Behnampour N, Tapak L, Zarrin Z, Khazaei S, et al. Machine learning-based evaluation of prognostic factors for mortality and relapse in patients with acute lymphoblastic leukemia: a comparative simulation study. BMC Med Inform Decis Mak. 2024;24(1):261.##Saleem M, Aslam W, Lali MIU, Rauf HT, Nasr EA. Predicting thalassemia using feature selection techniques: A comparative analysis. Diagnostics. 2023;13(22):3441.## ##

Comparative Evaluation of Custom Convolutional Neural Networks and EfficientNet-B3 for Malaria Cell Image Classification: Impact of Targeted Data Augmentation on Model Performance 2 2 Background: Malaria diagnosis with thin blood smears remains labor-intensive and relies on the operator. Deep learning could enable accurate automation. Objective: Compare four convolutional approaches for classifying parasitized versus uninfected erythrocytes and to evaluate whether targeted image-quality augmentations enhance performance. Materials and Methods: We used the balanced NIH/Kaggle dataset, which included 13,780 parasitized and 13,780 uninfected samples. Data were split stratified into training, validation, and test sets (70/15/15). Images were resized to 256×256 and normalized. Four experiments were conducted: (1) a custom CNN; (2) the same CNN with targeted augmentation applied to 20% of training samples per class—using Contrast Limited Adaptive Histogram Equalization [CLAHE] and controlled brightness adjustment—and augmented images were added back to the training set (totaling 30,864 images); (3) a soft-attention parallel CNN (SPCNN); and (4) transfer learning with EfficientNet-B3 on 300×300 inputs with full fine-tuning. Evaluation metrics included accuracy, precision, recall, F1 score, and AUC-ROC. Results: EfficientNet-B3 achieved the highest performance with a validation accuracy of 0.9741, 98% precision, 96% recall, an F1 score of 0.97, and an AUC-ROC of 0.9964. SPCNN was competitive but slightly lower, with a validation accuracy of 0.9652, 98% precision, 95% recall, an F1 score of 0.96, and an AUC-ROC of 0.9909. The baseline CNN had a validation accuracy of 0.9649, 97% precision, 94% recall, an F1 score of 0.96, and an AUC-ROC of 0.9910. Targeted augmentation resulted in negligible change compared to the baseline CNN, with a validation accuracy of 0.9647, an F1 score of 0.96, and an AUC-ROC of 0.9908, indicating limited added discriminative value for this dataset. Conclusion: EfficientNet-B3 outperformed SPCNN and custom CNNs. The CLAHE/brightness strategy applied to 20% of training images and added back to the dataset did not significantly improve generalization. External validation and prospective field testing are necessary before clinical deployment. 62 72 2025/07/42025/07/142025/08/192025/07/242025/07/172025/08/102025/07/10 1404/4/19 2025/09/242025/09/112025/09/112025/09/112025/09/172025/09/252025/09/10 1404/6/19 Reza Mohit Reza Mohit Department of Anesthesia, School of Paramedical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran Emad Milani Emad Milani Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran Ata Amini Ata Amini Department of Health Information Management and Medical Informatics, School of Allied Medical Sciences, Tehran University of Medical Sciences, Tehran, Iran Mehrnaz Ahani Mehrnaz Ahani Department of Midwifery, School of Nursing and Midwifery, Shahid Beheshti University of Medical Sciences, Tehran, Iran Elham Nazari Elham Nazari Proteomics Research Center, Faculty of Paramedical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran. elham.nazari@sbmu.ac.ir Tahmineh Aldaghi Tahmineh Aldaghi Institute of Biophysics and Informatics, First Faculty of Medicine, Charles University, Prague, Czech Republic. tahmineh1989@gmail.com Malaria Deep learning EfficientNet-B3 Albumentations Parasitized cell images Medical imaging AI Soft-attention parallel CNN World Health Organization. World Malaria Report 2024. Geneva: WHO; 2024.##Venkatesan P. WHO World Malaria Report 2024. Lancet Microbe. 2025;6(1).##Jones S, et al. Trends in Plasmodium burden in children and pregnant women in the WHO African Region. Lancet Glob Health. 2024.##RTS,S Clinical Trials Partnership. Efficacy and safety of RTS,S/AS01 malaria vaccine. Lancet. 2015;386(9988):31-45.##Datoo MS, et al. Efficacy of R21/Matrix-M malaria vaccine. Lancet. 2021;397(10287):1809-18.##Moody A. Rapid diagnostic tests for malaria parasites. Clin Microbiol Rev. 2002;15(1):66-78.##WHO. Malaria Microscopy Quality Assurance Manual, 2023.##Hopkins H, et al. Microscopy in malaria diagnosis. Malaria J. 2007;6:115.##Gamboa D, et al. A large proportion of P. falciparum in Peru lack pfhrp2 and pfhrp3. J Clin Microbiol. 2010;48(6):2055-7.##Snounou G. PCR diagnosis of malaria. Clin Microbiol Rev. 1993;6(1):15-28.##Rajaraman S, et al. Transfer learning for malaria parasite detection in thin smear images. PeerJ. 2018;6:e4568.##Pattanaik D, et al. Comparison of CNN frameworks for malaria diagnosis. arXiv preprint arXiv:1909.02829.##Liang Z, et al. CNN-based parasite stage classification. Comput Biol Med. 2021;134:104524.##Ahuja S, et al. EfficientNet B3-based malaria parasite detection. Biomed Signal Process Control. 2020;62:102093.##Tan M, Le Q. EfficientNet: Rethinking model scaling. ICML. 2019.##Shorten C, Khoshgoftaar TM. A survey on image data augmentation. J Big Data. 2019;6:60.##Perez L, Wang J. Effectiveness of data augmentation. arXiv preprint arXiv:1712.04621.##Ahamed F, et al. SPCNN for malaria detection. Sci Rep. 2025;15:6484.##Rajaraman S, Antani SK, Poostchi M, et al. Pre-trained convolutional neural networks as feature extractors toward improved malaria parasite detection in thin blood smear images. PeerJ. 2018;6:e4568.##Poostchi M, Silamut K, Maude RJ, Jaeger S, Thoma G. Image analysis and machine learning for detecting malaria. Trans R Soc Trop Med Hyg. 2018;112(4):170-182.##Kaggle. Cell Images for Malaria Detection dataset. Available at: https://www.kaggle.com/datasets/iarunava/cell-images-for-malaria. Accessed 2025.##Li X, Wang Y, Zhang J, et al. Attention-based parallel CNN architectures for interpretable malaria diagnosis. Sci Rep. 2024;14:12345.##Shorten C, Khoshgoftaar TM. A survey on image data augmentation for deep learning. J Big Data. 2019;6:60.##Tan M, Le QV. EfficientNet: Rethinking model scaling for convolutional neural networks. Proc Int Conf Mach Learn. 2019:6105-6114.##(Dataset): https://www.kaggle.com/datasets/iarunava/cell-images-for-detecting-malaria##Shorten C, Khoshgoftaar TM. A survey on image data augmentation for deep learning. J Big Data. 2019;6(1):60.##Perez L, Wang J. The effectiveness of data augmentation in image classification using deep learning. arXiv preprint arXiv:1712.04621.##Ahamed F, et al. SPCNN vs transfer learning on malaria detection. Sci Rep. 2025;15:6484.##Tan M, Le QV. EfficientNet: Rethinking model scaling for convolutional neural networks. ICML. 2019.##Silva, R. R. et al. (2022). Malaria Parasite Detection using EfficientNet Models. Biomedical Signal Processing and Control, 74, 103557.##Lundervold, A. S., & Lundervold, A. (2019). An overview of deep learning in medical imaging focusing on MRI. Zeitschrift für Medizinische Physik, 29(2), 102-127.##Kim DW, Jang HY, Kim KW, Shin Y, Park SH. Design characteristics of studies reporting the performance of artificial intelligence algorithms for diagnostic analysis of medical images: Results from recently published papers. Radiol Artif Intell. 2022;4(1):e210064.## ##

Assessment of Lysosome-Associated Membrane Protein (LAMP5) in Newly Diagnosed Multiple Myeloma Patients and Correlation to Clinical Outcome 2 2 Introduction: Lysosome-associated membrane protein 5(LAMP5) is one of the glycosylated proteins which are implicated in several different features of cell biology and can impact cellular processes for instance phagocytosis, autophagy, lipid transference, and aging. Interestingly, it has a significant role in cancer progression, metastatic spread and aggressiveness. It has been reported to be significantly expressed in many hematopoietic malignancies as leukemias and Multiple Myeloma (MM). Objectives: This study used enzyme-linked immunosorbent assay (ELISA) to measure the level of LAMP5 in newly diagnosed MM patients, and the level was correlated to the clinical outcome of the patient. Methods: A prospective study was done on 64 people, including 32 newly diagnosed MM patients and 32 age- and gender-matched healthy controls. ELISA was used to assess the levels of LAMP5 in serum samples. Clinical data and LAMP5 expression correlations were assessed. Results: MM patients’ LAMP5 levels were found to be statistically significantly higher than those of healthy controls (P<0.0001), However, LAMP5 does not correlate with clinical outcomes, laboratory results, or patient clinical data. Conclusion: This report emphasizes that LAMP5 expression in newly diagnosed multiple myeloma patients was highly significant by ELISA and its influence on patient’s prognosis still unclear as there was no significant correlation with other clinical data, which indicates more research on large scale of patients to determine its significance of its expression on prognosis. 73 78 2025/07/42025/07/142025/08/192025/07/242025/07/172025/08/102025/07/102025/08/11 1404/5/20 2025/09/242025/09/112025/09/112025/09/112025/09/172025/09/252025/09/102025/09/25 1404/7/3 Nahed Moawad Ibrahim Rakha Nahed Moawad Ibrahim Rakha Department of Internal Medicine and Clinical Hematology, Faculty of Medicine, Ain Shams University, Cairo, Egypt. nahedrakha@med.asu.edu.eg Amal Elaffifi Amal Elaffifi Department of Internal Medicine and Clinical Hematology, Faculty of Medicine, Ain Shams University, Cairo, Egypt. Rana Abbas Rana Abbas Department of Internal Medicine and Clinical Hematology, Faculty of Medicine, Ain Shams University, Cairo, Egypt. Ghada Mged Ghada Mged Department of clinical pathology, Faculty of Medicine, Ain Shams University, Cairo, Egypt. Shrouk Salah Shrouk Salah Department of Internal Medicine and Clinical Hematology, Faculty of Medicine, Ain Shams University, Cairo, Egypt. Haydi Sayed Haydi Sayed Department of Internal Medicine and Clinical Hematology, Faculty of Medicine, Ain Shams University, Cairo, Egypt. LAMP5 Multiple Myeloma Prognosis Ledergor, G., Weiner, A., Zada, M. et al. (2018). Single cell dissection of plasma cell heterogeneity in symptomatic and asymptomatic myeloma. Nat Med 24, 1867-1876.##Gracia-Maldonado G, Clark J, Burwinkel M, et al ., (2022). LAMP-5 is an essential inflammatory-signaling regulator and novel immunotherapy target for mixed lineage leukemia-rearranged acute leukemia. Haematologica.; 107(4):803-815.##Gracia-Maldonado, G., Clark, J., Pierre, P., et al ., (2018). The Role of LAMP5 in Innate Immune Signaling Is Critical for the Survival of MLL Leukemias. Blood, 132, 3900.##Rajkumar, S., Dimopoulos, M., Palumbo, A. (2014). International Myeloma Working Group Updated Criteria for the Diagnosis of Multiple Myeloma. The Lancet Oncology, 15(12), e538-548.##Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, et al., (2015). Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. J Clin Oncol. 10;33(26):2863-9.##Martin W. Schoen, Suhong Luo, Brian Gage, Kenneth Robert Carson, Kristen Marie Sanfilippo, (2018). Journal of Clinical Oncology, 36:15_suppl, 8051-8051.##Harousseau, J. L., Attal, M., & Avet-Loiseau, H.et al ., (2009). The role of complete response in multiple myeloma. Blood, The Journal of the American Society of Hematology, 114(15), 3139-3146##de Larrea C. F., Tovar N., Rozman M et al ., (2011). Multiple myeloma in serologic complete remission after autologous stem cell transplantation: impact of bone marrow plasma cell assessment by conventional morphology on disease progression. Biology of blood transplantation, 17(7), 1084-1087.##Harousseau, J. L., Attal, M., & Avet-Loiseau, H.et al ., (2009). The role of complete response in multiple myeloma. Blood, The Journal of the American Society of Hematology, 114(15), 3139-3146.##Umeda S, Kanda M, Shimizu D, et al., (2022). Lysosomal associated Membrane Protein Family Member 5 Promotes the Metastatic Potential of Gastric Cancer Cells. Gastric Cancer; 25(3):558-72.##Chen, Y., & Ma, T. (2023). LAMP5 may promote MM progression by activating p38. Pathology and Oncology Research, 29, 1611083.##Wang, H., Rueda, L. Y. M., Dang, M., Lee, et al ., (2023). Lysosomal Associated Membrane Protein Family Member 5 (LAMP5) As a Novel Mediator of, and Target in High Risk Multiple Myeloma (MM). Blood, 142, 873.## ##

The Immune Microenvironment in Acute Myeloid Leukemia: Mechanisms of Immune Evasion and Emerging Therapeutic Strategies 2 2 Acute Myeloid Leukemia (AML), a diverse type of blood cancer, is characterized by the unchecked multiplication of myeloid precursor cells within a disrupted bone marrow microenvironment (BMM). Leukemic blasts alter the BMM to create a leukemia niche, promoting immunological evasion and disease development. High relapse rates highlight the need for novel therapeutic approaches, even if chemotherapy is still the cornerstone of treatment. AML cells use many strategies to avoid immune identification, such as suppressing anti-leukemic immune responses and upregulating immune checkpoints. Immunotherapies like checkpoint inhibitors that target these pathways have shown encouraging promise. The intricate relationships between AML and the immunological milieu are examined in this review, with a focus on immune evasion, treatment resistance, and innovative immunotherapeutic strategies to improve anti-leukemic immunity. 79 95 2025/07/42025/07/142025/08/192025/07/242025/07/172025/08/102025/07/102025/08/112025/07/21 1404/4/30 2025/09/242025/09/112025/09/112025/09/112025/09/172025/09/252025/09/102025/09/252025/09/11 1404/6/20 Vinod Kumar Singh Vinod Kumar Singh Department of General Medicine, Teerthanker Mahaveer Medical College & Research Centre, Teerthanker Mahaveer University, Moradabad, Uttar Pradesh, India. drvinodkumarsingh85@gmail.com Prithpal Singh Matreja Prithpal Singh Matreja Department of Pharmacology, Teerthanker Mahaveer Medical College & Research Centre, Teerthanker Mahaveer University, Moradabad, Uttar Pradesh, India. Sudhir Singh Sudhir Singh Department of microbiology, Teerthanker Mahaveer Medical College & Research Centre, Teerthanker Mahaveer University, Moradabad, Uttar Pradesh, India. Seema Awasthi Seema Awasthi Department of pathology, Teerthanker Mahaveer Medical College & Research Centre, Teerthanker Mahaveer University, Moradabad, Uttar Pradesh, India. Acute Myeloid Leukemia Hematological malignancies Cytogenetics Testa U, Castelli G, Pelosi E. Recent Developments in Differentiation Therapy of Acute Myeloid Leukemia. 2025;##Ladikou EE, Sivaloganathan H, Pepper A, Chevassut T. Acute myeloid leukaemia in its niche: the bone marrow microenvironment in acute myeloid leukaemia. Curr Oncol Rep. 2020;22:1-9.##Sendker S, Reinhardt D, Niktoreh N. Redirecting the immune microenvironment in acute myeloid leukemia. Cancers (Basel). 2021;13(6):1423.##Zhang M, Yang Y, Liu J, Guo L, Guo Q, Liu W. Bone marrow immune cells and drug resistance in acute myeloid leukemia. Exp Biol Med. 2025;250:10235.##Döhner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. New England Journal of Medicine. 2015;373(12):1136-52.##Luppi M, Fabbiano F, Visani G, Martinelli G, Venditti A. Novel agents for acute myeloid leukemia. Cancers (Basel). 2018;10(11):429.##Sun H, Li Y, Zhang Z fen, Ju Y, Li L, Zhang B chang, et al. Increase in myeloid-derived suppressor cells (MDSCs) associated with minimal residual disease (MRD) detection in adult acute myeloid leukemia. Int J Hematol. 2015;102:579-86.##Teague RM, Kline J. Immune evasion in acute myeloid leukemia: current concepts and future directions. J Immunother Cancer. 2013;1:1-11.##Wang A, Zhong H. Roles of the bone marrow niche in hematopoiesis, leukemogenesis, and chemotherapy resistance in acute myeloid leukemia. Hematology. 2018;23(10):729-39.##Taghiloo S, Asgarian-Omran H. Current approaches of immune checkpoint therapy in chronic lymphocytic leukemia. Curr Treat Options Oncol. 2023;24(10):1408-38.##Tikhonova AN, Dolgalev I, Hu H, Sivaraj KK, Hoxha E, Cuesta-Domínguez Á, et al. The bone marrow microenvironment at single-cell resolution. Nature. 2019;569(7755):222-8.##Comazzetto S, Shen B, Morrison SJ. Niches that regulate stem cells and hematopoiesis in adult bone marrow. Dev Cell. 2021;56(13):1848-60.##Baryawno N, Przybylski D, Kowalczyk MS, Kfoury Y, Severe N, Gustafsson K, et al. A cellular taxonomy of the bone marrow stroma in homeostasis and leukemia. Cell. 2019;177(7):1915-32.##Méndez-Ferrer S, Bonnet D, Steensma DP, Hasserjian RP, Ghobrial IM, Gribben JG, et al. Bone marrow niches in haematological malignancies. Nat Rev Cancer. 2020;20(5):285-98.##Raaijmakers MHGP, Mukherjee S, Guo S, Zhang S, Kobayashi T, Schoonmaker JA, et al. Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia. Nature. 2010;464(7290):852-7.##Walkley CR, Olsen GH, Dworkin S, Fabb SA, Swann J, McArthur GA, et al. A microenvironment-induced myeloproliferative syndrome caused by retinoic acid receptor γ deficiency. Cell. 2007;129(6):1097-110.##Ho YH, Del Toro R, Rivera-Torres J, Rak J, Korn C, García-García A, et al. Remodeling of bone marrow hematopoietic stem cell niches promotes myeloid cell expansion during premature or physiological aging. Cell Stem Cell. 2019;25(3):407-18.##Mendelson A, Frenette PS. Hematopoietic stem cell niche maintenance during homeostasis and regeneration. Nat Med. 2014;20(8):833-46.##Maryanovich M, Zahalka AH, Pierce H, Pinho S, Nakahara F, Asada N, et al. Adrenergic nerve degeneration in bone marrow drives aging of the hematopoietic stem cell niche. Nat Med. 2018;24(6):782-91.##Arranz L, Sánchez-Aguilera A, Martín-Pérez D, Isern J, Langa X, Tzankov A, et al. Neuropathy of haematopoietic stem cell niche is essential for myeloproliferative neoplasms. Nature. 2014;512(7512):78-81.##Grockowiak E, Korn C, Rak J, Lysenko V, Hallou A, Panvini FM, et al. Different niches for stem cells carrying the same oncogenic driver affect pathogenesis and therapy response in myeloproliferative neoplasms. Nat Cancer. 2023;4(8):1193-209.##Li R, Zhou Y, Cao Z, Liu L, Wang J, Chen Z, et al. TET2 loss dysregulates the behavior of bone marrow mesenchymal stromal cells and accelerates Tet2−/−-driven myeloid malignancy progression. Stem Cell Reports. 2018;10(1):166-79.##Zhang P, Chen Z, Li R, Guo Y, Shi H, Bai J, et al. Loss of ASXL1 in the bone marrow niche dysregulates hematopoietic stem and progenitor cell fates. Cell Discov. 2018;4(1):4.##https://doi.org/10.1038/s41421-017-0004-z##SanMiguel JM, Eudy E, Loberg MA, Young KA, Mistry JJ, Mujica KD, et al. Distinct tumor necrosis factor alpha receptors dictate stem cell fitness versus lineage output in Dnmt3a-mutant clonal hematopoiesis. Cancer Discov. 2022;12(12):2763-73.##Hanoun M, Zhang D, Mizoguchi T, Pinho S, Pierce H, Kunisaki Y, et al. Acute myelogenous leukemia-induced sympathetic neuropathy promotes malignancy in an altered hematopoietic stem cell niche. Cell Stem Cell. 2014;15(3):365-75.##Rios de los Rios J, Enciso J, Vilchis-Ordoñez A, Vázquez-Ramírez R, Ramirez-Ramirez D, Balandrán JC, et al. Acute lymphoblastic leukemia-secreted miRNAs induce a proinflammatory microenvironment and promote the activation of hematopoietic progenitors. J Leukoc Biol. 2022;112(1):31-45.##Balandrán JC, Purizaca J, Enciso J, Dozal D, Sandoval A, Jiménez-Hernández E, et al. Pro-inflammatory-related loss of CXCL12 niche promotes acute lymphoblastic leukemic progression at the expense of normal lymphopoiesis. Front Immunol. 2017;7:666.##Agarwal P, Isringhausen S, Li H, Paterson AJ, He J, Gomariz Á, et al. Mesenchymal niche-specific expression of Cxcl12 controls quiescence of treatment-resistant leukemia stem cells. Cell Stem Cell. 2019;24(5):769-84.##Schneider RK, Mullally A, Dugourd A, Peisker F, Hoogenboezem R, Van Strien PMH, et al. Gli1+ mesenchymal stromal cells are a key driver of bone marrow fibrosis and an important cellular therapeutic target. Cell Stem Cell. 2017;20(6):785-800.##Zehtabcheh S, Yousefi AM, Salari S, Safa M, Momeny M, Ghaffari SH, Bashash D. Abrogation of histone deacetylases (HDACs) decreases survival of chronic myeloid leukemia cells: New insight into attenuating effects of the PI3K/c‐Myc axis on panobinostat cytotoxicity. Cell Biology International. 2021 May;45(5):1111-21.##Medyouf H, Mossner M, Jann JC, Nolte F, Raffel S, Herrmann C, et al. Myelodysplastic cells in patients reprogram mesenchymal stromal cells to establish a transplantable stem cell niche disease unit. Cell Stem Cell. 2014;14(6):824-37.##Decker M, Martinez-Morentin L, Wang G, Lee Y, Liu Q, Leslie J, et al. Leptin-receptor-expressing bone marrow stromal cells are myofibroblasts in primary myelofibrosis. Nat Cell Biol. 2017;19(6):677-88.##Barbier V, Erbani J, Fiveash C, Davies JM, Tay J, Tallack MR, et al. Endothelial E-selectin inhibition improves acute myeloid leukaemia therapy by disrupting vascular niche-mediated chemoresistance. Nat Commun. 2020;11(1):2042.##Duarte D, Hawkins ED, Akinduro O, Ang H, De Filippo K, Kong IY, et al. Inhibition of endosteal vascular niche remodeling rescues hematopoietic stem cell loss in AML. Cell Stem Cell. 2018;22(1):64-77.##Schmidt T, Masouleh BK, Loges S, Cauwenberghs S, Fraisl P, Maes C, et al. Loss or inhibition of stromal-derived PlGF prolongs survival of mice with imatinib-resistant Bcr-Abl1+ leukemia. Cancer Cell. 2011;19(6):740-53.##Deschler B, Lübbert M. Acute myeloid leukemia: epidemiology and etiology. Cancer: Interdisciplinary International Journal of the American Cancer Society. 2006;107(9):2099-107.##Estey E, Döhner H. Acute myeloid leukaemia. The Lancet. 2006;368(9550):1894-907.##Shallis RM, Wang R, Davidoff A, Ma X, Zeidan AM. Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges. Blood Rev. 2019;36:70-87.##Patel JP, Gönen M, Figueroa ME, Fernandez H, Sun Z, Racevskis J, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. New England Journal of Medicine. 2012;366(12):1079-89.##DiNardo CD, Cortes JE. Mutations in AML: prognostic and therapeutic implications. Hematology 2014, the American Society of Hematology Education Program Book. 2016;2016(1):348-55.##Martelli MP, Sportoletti P, Tiacci E, Martelli MF, Falini B. Mutational landscape of AML with normal cytogenetics: biological and clinical implications. Blood Rev. 2013;27(1):13-22.##Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, et al. Genomic classification and prognosis in acute myeloid leukemia. New England Journal of Medicine. 2016;374(23):2209-21.##Eisfeld AK, Kohlschmidt J, Mims A, Nicolet D, Walker CJ, Blachly JS, et al. Additional gene mutations may refine the 2017 European LeukemiaNet classification in adult patients with de novo acute myeloid leukemia aged< 60 years. Leukemia. 2020;34(12):3215-27.##Narayanan D, Weinberg OK. How I investigate acute myeloid leukemia. Int J Lab Hematol. 2020;42(1):3-15.##Weinberg OK, Hasserjian RP, Baraban E, Ok CY, Geyer JT, Philip JKSS, et al. Clinical, immunophenotypic, and genomic findings of acute undifferentiated leukemia and comparison to acute myeloid leukemia with minimal differentiation: a study from the bone marrow pathology group. Modern Pathology. 2019;32(9):1373-85.##Rose-Inman H, Kuehl D. Acute leukemia. Hematology/Oncology Clinics. 2017;31(6):1011-28.##Franchini M, Frattini F, Crestani S, Bonfanti C. Bleeding complications in patients with hematologic malignancies. In: Seminars in thrombosis and hemostasis. Thieme Medical Publishers; 2013. p. 94-100.##Naymagon L, Mascarenhas J. Hemorrhage in acute promyelocytic leukemia: Can it be predicted and prevented? Leuk Res. 2020;94:106356.##Stahl M, Shallis RM, Wei W, Montesinos P, Lengline E, Neukirchen J, et al. Management of hyperleukocytosis and impact of leukapheresis among patients with acute myeloid leukemia (AML) on short-and long-term clinical outcomes: a large, retrospective, multicenter, international study. Leukemia. 2020;34(12):3149-60.##Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood, the journal of the american society of hematology. 2016;127(20):2391-405.##Jongen-Lavrencic M, Grob T, Hanekamp D, Kavelaars FG, Al Hinai A, Zeilemaker A, et al. Molecular minimal residual disease in acute myeloid leukemia. New England Journal of Medicine. 2018;378(13):1189-99.##De Kouchkovsky I, Abdul-Hay M. Acute myeloid leukemia: a comprehensive review and 2016 update. Blood Cancer J. 2016;6(7):e441-e441.##Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood, The Journal of the American Society of Hematology. 2017;129(4):424-47.##DiNardo CD, Maiti A, Rausch CR, Pemmaraju N, Naqvi K, Daver NG, et al. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. Lancet Haematol. 2020;7(10):e724-36.##Wei AH, Montesinos P, Ivanov V, DiNardo CD, Novak J, Laribi K, et al. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. Blood, The Journal of the American Society of Hematology. 2020;135(24):2137-45.##Datoguia TS, Velloso EDRP, Helman R, Musacchio JG, Salvino MA, Soares RA, et al. Overall survival of Brazilian acute myeloid leukemia patients according to the European LeukemiaNet prognostic scoring system: a cross-sectional study. Medical Oncology. 2018;35:1-6.##Shimomura Y, Hara M, Konuma T, Itonaga H, Doki N, Ozawa Y, et al. Allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome in adolescent and young adult patients. Bone Marrow Transplant. 2021;56(10):2510-7.##Hirabayashi S, Uozumi R, Kondo T, Arai Y, Kawata T, Uchida N, et al. Personalized prediction of overall survival in patients with AML in non‐complete remission undergoing allo‐HCT. Cancer Med. 2021;10(13):4250-68.##Daver N, Wei AH, Pollyea DA, Fathi AT, Vyas P, DiNardo CD. New directions for emerging therapies in acute myeloid leukemia: the next chapter. Blood Cancer J. 2020;10(10):107.##O'Donnell MR, Tallman MS, Abboud CN, Altman JK, Appelbaum FR, Arber DA, et al. Acute myeloid leukemia, version 3.2017, NCCN clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network. 2017;15(7):926-57.##Puccetti E, Ruthardt M. Acute promyelocytic leukemia: PML/RARα and the leukemic stem cell. Leukemia. 2004;18(7):1169-75.##Mistry AR, Pedersen EW, Solomon E, Grimwade D. The molecular pathogenesis of acute promyelocytic leukaemia: implications for the clinical management of the disease. Blood Rev. 2003;17(2):71-97.##Burnett AK, Russell NH, Hills RK, Bowen D, Kell J, Knapper S, et al. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial. Lancet Oncol. 2015;16(13):1295-305.##Zhang P, Zhang C, Li J, Han J, Liu X, Yang H. The physical microenvironment of hematopoietic stem cells and its emerging roles in engineering applications. Stem Cell Res Ther. 2019;10:1-13.##Brück O, Dufva O, Hohtari H, Blom S, Turkki R, Ilander M, et al. Immune profiles in acute myeloid leukemia bone marrow associate with patient age, T-cell receptor clonality, and survival. Blood Adv. 2020;4(2):274-86.##Black S, Phillips D, Hickey JW, Kennedy-Darling J, Venkataraaman VG, Samusik N, et al. CODEX multiplexed tissue imaging with DNA-conjugated antibodies. Nat Protoc. 2021;16(8):3802-35.##Bandyopadhyay S, Duffy MP, Ahn KJ, Sussman JH, Pang M, Smith D, et al. Mapping the cellular biogeography of human bone marrow niches using single-cell transcriptomics and proteomic imaging. Cell. 2024;187(12):3120-40.##Passaro D, Di Tullio A, Abarrategi A, Rouault-Pierre K, Foster K, Ariza-McNaughton L, et al. Increased vascular permeability in the bone marrow microenvironment contributes to disease progression and drug response in acute myeloid leukemia. Cancer Cell. 2017;32(3):324-41.##Kumar B, Garcia M, Weng L, Jung X, Murakami JL, Hu X, et al. Acute myeloid leukemia transforms the bone marrow niche into a leukemia-permissive microenvironment through exosome secretion. Leukemia. 2018;32(3):575-87.##Munn DH, Mellor AL, Rossi M, Young JW. Dendritic cells have the option to express IDO-mediated suppression or not. Blood. 2005;105(6):2618.##Mussai F, De Santo C, Abu-Dayyeh I, Booth S, Quek L, McEwen-Smith RM, et al. Acute myeloid leukemia creates an arginase-dependent immunosuppressive microenvironment. Blood, The Journal of the American Society of Hematology. 2013;122(5):749-58.##Serra S, Horenstein AL, Vaisitti T, Brusa D, Rossi D, Laurenti L, et al. CD73-generated extracellular adenosine in chronic lymphocytic leukemia creates local conditions counteracting drug-induced cell death. Blood, The Journal of the American Society of Hematology. 2011;118(23):6141-52.##Dulphy N, Henry G, Hemon P, Khaznadar Z, Dombret H, Boissel N, et al. Contribution of CD39 to the immunosuppressive microenvironment of acute myeloid leukaemia at diagnosis. Br J Haematol. 2014;165(5).##de la Guardia RD, Lopez-Millan B, Lavoie JR, Bueno C, Castano J, Gómez-Casares M, et al. Detailed characterization of mesenchymal stem/stromal cells from a large cohort of AML patients demonstrates a definitive link to treatment outcomes. Stem Cell Reports. 2017;8(6):1573-86.##Carey A, Edwards DK, Eide CA, Newell L, Traer E, Medeiros BC, et al. Identification of interleukin-1 by functional screening as a key mediator of cellular expansion and disease progression in acute myeloid leukemia. Cell Rep. 2017;18(13):3204-18.##Mishra SK, Millman SE, Zhang L. Metabolism in acute myeloid leukemia: mechanistic insights and therapeutic targets. Blood. 2023;141(10):1119-35.##Wang ZH, Peng WB, Zhang P, Yang XP, Zhou Q. Lactate in the tumour microenvironment: From immune modulation to therapy. EBioMedicine 73, 103627. 2021.##Sabuncuoğlu S, Öztaş Y, Uçkan Çetinkaya D, Özgüneş N, Özgüneş H. Oxidative protein damage with carbonyl levels and nitrotyrosine expression after chemotherapy in bone marrow transplantation patients. Pharmacology. 2012;89(5-6):283-6.##Kong H, Chandel NS. Regulation of redox balance in cancer and T cells. Journal of Biological Chemistry. 2018;293(20):7499-507.##Toffalori C, Zito L, Gambacorta V, Riba M, Oliveira G, Bucci G, et al. Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation. Nat Med. 2019;25(4):603-11.##Christopher MJ, Petti AA, Rettig MP, Miller CA, Chendamarai E, Duncavage EJ, et al. Immune escape of relapsed AML cells after allogeneic transplantation. New England Journal of Medicine. 2018;379(24):2330-41.##Noviello M, Manfredi F, Ruggiero E, Perini T, Oliveira G, Cortesi F, et al. Bone marrow central memory and memory stem T-cell exhaustion in AML patients relapsing after HSCT. Nat Commun. 2019;10(1):1065.##Jain P, Tian X, Cordes S, Chen J, Cantilena CR, Bradley C, et al. Over-expression of PD-1 does not predict leukemic relapse after allogeneic stem cell transplantation. Biology of Blood and Marrow Transplantation. 2019;25(2):216-22.##Kong Y, Zhang J, Claxton DF, Ehmann WC, Rybka WB, Zhu L, et al. PD-1hiTIM-3+ T cells associate with and predict leukemia relapse in AML patients post allogeneic stem cell transplantation. Blood Cancer J. 2015;5(7):e330-e330.##Williams P, Basu S, Garcia‐Manero G, Hourigan CS, Oetjen KA, Cortes JE, et al. The distribution of T‐cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia. Cancer. 2019;125(9):1470-81.##Yeaton A, Cayanan G, Loghavi S, Dolgalev I, Leddin EM, Loo CE, et al. The impact of inflammation-induced tumor plasticity during myeloid transformation. Cancer Discov. 2022;12(10):2392-413.##Guo R, Lü M, Cao F, Wu G, Gao F, Pang H, et al. Single-cell map of diverse immune phenotypes in the acute myeloid leukemia microenvironment. Biomark Res. 2021;9:1-16.##Mundy-Bosse BL, Scoville SD, Chen L, McConnell K, Mao HC, Ahmed EH, et al. MicroRNA-29b mediates altered innate immune development in acute leukemia. J Clin Invest. 2016;126(12):4404-16.##Lasry A, Nadorp B, Fornerod M, Nicolet D, Wu H, Walker CJ, et al. An inflammatory state remodels the immune microenvironment and improves risk stratification in acute myeloid leukemia. Nat Cancer. 2023;4(1):27-42.##Mumme H, Thomas BE, Bhasin SS, Krishnan U, Dwivedi B, Perumalla P, et al. Single-cell analysis reveals altered tumor microenvironments of relapse-and remission-associated pediatric acute myeloid leukemia. Nat Commun. 2023;14(1):6209.##Abbas HA, Hao D, Tomczak K, Barrodia P, Im JS, Reville PK, et al. Single cell T cell landscape and T cell receptor repertoire profiling of AML in context of PD-1 blockade therapy. Nat Commun. 2021;12(1):6071.##Knaus HA, Berglund S, Hackl H, Blackford AL, Zeidner JF, Montiel-Esparza R, et al. Signatures of CD8+ T cell dysfunction in AML patients and their reversibility with response to chemotherapy. JCI Insight. 2018;3(21):e120974.##Zeiser R, Vago L. Mechanisms of immune escape after allogeneic hematopoietic cell transplantation. Blood, The Journal of the American Society of Hematology. 2019;133(12):1290-7.##McCurdy SR, Iglehart BS, Batista DA, Gocke CD, Ning Y, Knaus HA, et al. Loss of the mismatched human leukocyte antigen haplotype in two acute myelogenous leukemia relapses after haploidentical bone marrow transplantation with post-transplantation cyclophosphamide. Leukemia. 2016;30(10):2102-6.##Kline DE, MacNabb BW, Chen X, Chan WC, Fosco D, Kline J. CD8α+ dendritic cells dictate leukemia-specific CD8+ T cell fates. The Journal of Immunology. 2018;201(12):3759-69.##Xiao W, Goldberg AD, Famulare CA, Devlin SM, Nguyen NT, Sim S, et al. Loss of plasmacytoid dendritic cell differentiation is highly predictive for post-induction measurable residual disease and inferior outcomes in acute myeloid leukemia. Haematologica. 2018;104(7):1378.##Ismail MM, Abdulateef NAB. Bone marrow T-cell percentage: A novel prognostic indicator in acute myeloid leukemia. Int J Hematol. 2017;105:453-64.##Behl D, Porrata LF, Markovic SN, Letendre L, Pruthi RK, Hook CC, et al. Absolute lymphocyte count recovery after induction chemotherapy predicts superior survival in acute myelogenous leukemia. Leukemia. 2006;20(1):29-34.##Daver N, Garcia-Manero G, Basu S, Boddu PC, Alfayez M, Cortes JE, et al. Efficacy, safety, and biomarkers of response to azacitidine and nivolumab in relapsed/refractory acute myeloid leukemia: a nonrandomized, open-label, phase II study. Cancer Discov. 2019;9(3):370-83.##Zhou Q, Munger ME, Highfill SL, Tolar J, Weigel BJ, Riddle M, et al. Program death-1 signaling and regulatory T cells collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes in advanced acute myeloid leukemia. Blood, The Journal of the American Society of Hematology. 2010;116(14):2484-93.##Zhou Q, Munger ME, Veenstra RG, Weigel BJ, Hirashima M, Munn DH, et al. Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia. Blood, The Journal of the American Society of Hematology. 2011;117(17):4501-10.##Le Dieu R, Taussig DC, Ramsay AG, Mitter R, Miraki-Moud F, Fatah R, et al. Peripheral blood T cells in acute myeloid leukemia (AML) patients at diagnosis have abnormal phenotype and genotype and form defective immune synapses with AML blasts. Blood, The Journal of the American Society of Hematology. 2009;114(18):3909-16.##Schnorfeil FM, Lichtenegger FS, Emmerig K, Schlueter M, Neitz JS, Draenert R, et al. T cells are functionally not impaired in AML: increased PD-1 expression is only seen at time of relapse and correlates with a shift towards the memory T cell compartment. J Hematol Oncol. 2015;8:1-12.##Dama P, Tang M, Fulton N, Kline J, Liu H. Gal9/Tim-3 expression level is higher in AML patients who fail chemotherapy. J Immunother Cancer. 2019;7:1-7.##Radpour R, Riether C, Simillion C, Höpner S, Bruggmann R, Ochsenbein AF. CD8+ T cells expand stem and progenitor cells in favorable but not adverse risk acute myeloid leukemia. Leukemia. 2019;33(10):2379-92.##Brodská B, Otevřelová P, Šálek C, Fuchs O, Gašová Z, Kuželová K. High PD-L1 expression predicts for worse outcome of leukemia patients with concomitant NPM1 and FLT3 mutations. Int J Mol Sci. 2019;20(11):2823.##Yoyen-Ermis D, Tunali G, Tavukcuoglu E, Horzum U, Ozkazanc D, Sutlu T, et al. Myeloid maturation potentiates STAT3-mediated atypical IFN-γ signaling and upregulation of PD-1 ligands in AML and MDS. Sci Rep. 2019;9(1):11697.##Rettig MP, Godwin J, Vey N, Fox B, Ballesteros-Merino C, Bifulco CB, et al. Preliminary translational results from an ongoing phase 1 study of flotetuzumab, a CD123 x CD3 Dart®, in AML/MDS: rationale for combining flotetuzumab and anti-PD-1/PD-L1 immunotherapies. Blood. 2017;130:1365.##Aurelius J, Thorén FB, Akhiani AA, Brune M, Palmqvist L, Hansson M, et al. Monocytic AML cells inactivate antileukemic lymphocytes: role of NADPH oxidase/gp91phox expression and the PARP-1/PAR pathway of apoptosis. Blood, The Journal of the American Society of Hematology. 2012;119(24):5832-7.##Stringaris K, Sekine T, Khoder A, Alsuliman A, Razzaghi B, Sargeant R, et al. Leukemia-induced phenotypic and functional defects in natural killer cells predict failure to achieve remission in acute myeloid leukemia. Haematologica. 2014;99(5):836.##Elias S, Yamin R, Golomb L, Tsukerman P, Stanietsky-Kaynan N, Ben-Yehuda D, et al. Immune evasion by oncogenic proteins of acute myeloid leukemia. Blood, The Journal of the American Society of Hematology. 2014;123(10):1535-43.##Ustun C, Miller JS, Munn DH, Weisdorf DJ, Blazar BR. Regulatory T cells in acute myelogenous leukemia: is it time for immunomodulation? Blood, The Journal of the American Society of Hematology. 2011;118(19):5084-95.##Delia M, Carluccio P, Mestice A, Brunetti C, Albano F, Specchia G. Impact of bone marrow aspirate tregs on the response rate of younger newly diagnosed acute myeloid leukemia patients. J Immunol Res. 2018;2018(1):9325261.##Pyzer AR, Stroopinsky D, Rajabi H, Washington A, Tagde A, Coll M, et al. MUC1-mediated induction of myeloid-derived suppressor cells in patients with acute myeloid leukemia. Blood, The Journal of the American Society of Hematology. 2017;129(13):1791-801.##Kittang AO, Kordasti S, Sand KE, Costantini B, Kramer AM, Perezabellan P, et al. Expansion of myeloid derived suppressor cells correlates with number of T regulatory cells and disease progression in myelodysplastic syndrome. Oncoimmunology. 2016;5(2):e1062208.##Mangaonkar A, Mondal AK, Fulzule S, Pundkar C, Park EJ, Jillella A, et al. A novel immunohistochemical score to predict early mortality in acute myeloid leukemia patients based on indoleamine 2, 3 dioxygenase expression. Sci Rep. 2017;7(1):12892.##Curti A, Pandolfi S, Valzasina B, Aluigi M, Isidori A, Ferri E, et al. Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25− into CD25+ T regulatory cells. Blood. 2007;109(7):2871-7.##Deng M, Gui X, Kim J, Xie L, Chen W, Li Z, et al. LILRB4 signalling in leukaemia cells mediates T cell suppression and tumour infiltration. Nature. 2018;562(7728):605-9.##Hargadon KM, Johnson CE, Williams CJ. Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors. Int Immunopharmacol. 2018;62:29-39.##Liao D, Wang M, Liao Y, Li J, Niu T. A review of efficacy and safety of checkpoint inhibitor for the treatment of acute myeloid leukemia. Front Pharmacol. 2019;10:609.##Bashey A, Medina B, Corringham S, Pasek M, Carrier E, Vrooman L, et al. CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation. Blood, The Journal of the American Society of Hematology. 2009;113(7):1581-8.##Davids MS, Kim HT, Bachireddy P, Costello C, Liguori R, Savell A, et al. Ipilimumab for patients with relapse after allogeneic transplantation. New England Journal of Medicine. 2016;375(2):143-53.##Davids MS, Kim HT, Costello C, Herrera AF, Locke FL, Maegawa RO, et al. A multicenter phase 1 study of nivolumab for relapsed hematologic malignancies after allogeneic transplantation. Blood, The Journal of the American Society of Hematology. 2020;135(24):2182-91.##Berger R, Rotem-Yehudar R, Slama G, Landes S, Kneller A, Leiba M, et al. Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clinical Cancer Research. 2008;14(10):3044-51.##Chen C, Liang C, Wang S, Chio CL, Zhang Y, Zeng C, et al. Expression patterns of immune checkpoints in acute myeloid leukemia. J Hematol Oncol. 2020;13:1-5.##Assi HI, Kamphorst AO, Moukalled NM, Ramalingam SS. Immune checkpoint inhibitors in advanced non-small cell lung cancer. Cancer. 2018;124(2):248-61.##Daver N, Kantarjian H, Ravandi F, Estey E, Wang X, Garcia-Manero G, et al. A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome. Leukemia. 2016;30(2):268-73.##Ghosh A, Barba P, Perales M. Checkpoint inhibitors in AML: are we there yet? Br J Haematol. 2020;188(1):159-67.##Karim LA, Wang P, Guzman J de, Higgins B, Chahine J, Sheehan C, et al. PDL1 protein expression and tumor mutation burden in hematologic malignancies: correlation with Hodgkin and high grade lymphoma. Cancer Res. 2017;77(13_Supplement):3724.##Lindblad KE, Goswami M, Hourigan CS, Oetjen KA. Immunological effects of hypomethylating agents. Expert Rev Hematol. 2017;10(8):745-52.##Kikushige Y, Miyamoto T, Yuda J, Jabbarzadeh-Tabrizi S, Shima T, Takayanagi S ichiro, et al. A TIM-3/Gal-9 autocrine stimulatory loop drives self-renewal of human myeloid leukemia stem cells and leukemic progression. Cell Stem Cell. 2015;17(3):341-52.##Broglie L, Gershan J, Burke MJ. Checkpoint inhibition of PD-L1 and CTLA-4 in a child with refractory acute leukemia. Int J Hematol Oncol. 2019;8(1):IJH10.##Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ, et al. Graft-versus-leukemia reactions after bone marrow transplantation. 1990;##Sakellari I, Konstantinou V, Gavriilaki E, Mallouri D, Batsis I, Kalaitzidou V, et al. Efficacy and Toxicity of Donor Lymphocyte Infusions in Relapsed Acute Myeloid Leukemia Post Allogeneic Hematopoietic Cell Transplantation: Single-Center Experience. American Society of Hematology Washington, DC; 2016.##Mardiros A, Dos Santos C, McDonald T, Brown CE, Wang X, Budde LE, et al. T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia. Blood, The Journal of the American Society of Hematology. 2013;122(18):3138-48.##Kenderian SS, Ruella M, Shestova O, Klichinsky M, Aikawa V, Morrissette JJD, et al. CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia. Leukemia. 2015;29(8):1637-47.##Petrov JC, Wada M, Pinz KG, Yan LE, Chen KH, Shuai X, et al. Compound CAR T-cells as a double-pronged approach for treating acute myeloid leukemia. Leukemia. 2018;32(6):1317-26.##Vajari MK, Moradinasab S, Yousefi AM, Bashash D. Noncoding RNAs in diagnosis and prognosis of graft‐versus‐host disease (GVHD). Journal of Cellular Physiology. 2022 Sep;237(9):3480-95.##Xie G, Dong H, Liang Y, Ham JD, Rizwan R, Chen J. CAR-NK cells: A promising cellular immunotherapy for cancer. EBioMedicine. 2020;59.##Tettamanti S, Marin V, Pizzitola I, Magnani CF, Attianese GMG, Cribioli E, et al. Targeting of acute myeloid leukemia (AML) by cytokine-induced killer (CIK) cells redirected with a novel CD123-specific chimeric antigen receptor (CAR). Cytotherapy. 2013;15(4):S37.##Bednarski JJ, Zimmerman C, Cashen AF, Desai S, Foster M, Schappe T, et al. Adoptively transferred donor-derived cytokine induced memory-like NK cells persist and induce remission in pediatric patient with relapsed acute myeloid leukemia after hematopoietic cell transplantation. Blood. 2019;134:3307.##Tang X, Yang L, Li Z, Nalin AP, Dai H, Xu T, et al. First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia. Am J Cancer Res. 2018;8(6):1083.##Rubnitz JE, Inaba H, Ribeiro RC, Pounds S, Rooney B, Bell T, et al. NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. Journal of clinical oncology. 2010;28(6):955-9.##Curti A, Ruggeri L, D'Addio A, Bontadini A, Dan E, Motta MR, et al. Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients. Blood, The Journal of the American Society of Hematology. 2011;118(12):3273-9.##Nguyen R, Wu H, Pounds S, Inaba H, Ribeiro RC, Cullins D, et al. A phase II clinical trial of adoptive transfer of haploidentical natural killer cells for consolidation therapy of pediatric acute myeloid leukemia. J Immunother Cancer. 2019;7:1-7.##Curti A, Ruggeri L, Parisi S, Bontadini A, Dan E, Motta MR, et al. Larger size of donor alloreactive NK cell repertoire correlates with better response to NK cell immunotherapy in elderly acute myeloid leukemia patients. Clinical Cancer Research. 2016;22(8):1914-21.##Bachanova V, Cooley S, Defor TE, Verneris MR, Zhang B, McKenna DH, et al. Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein. Blood, The Journal of the American Society of Hematology. 2014;123(25):3855-63.##Bras AE, de Haas V, van Stigt A, Jongen‐Lavrencic M, Beverloo HB, Te Marvelde JG, et al. CD123 expression levels in 846 acute leukemia patients based on standardized immunophenotyping. Cytometry B Clin Cytom. 2019;96(2):134-42.##Morsink LM, Walter RB. Novel monoclonal antibody-based therapies for acute myeloid leukemia. Best Pract Res Clin Haematol. 2019;32(2):116-26.##Niktoreh N, Lerius B, Zimmermann M, Gruhn B, Escherich G, Bourquin JP, et al. Gemtuzumab ozogamicin in children with relapsed or refractory acute myeloid leukemia: a report by Berlin-Frankfurt-Münster study group. Haematologica. 2018;104(1):120.##Renneville A, Abdelali R Ben, Chevret S, Nibourel O, Cheok M, Pautas C, et al. Clinical impact of gene mutations and lesions detected by SNP-array karyotyping in acute myeloid leukemia patients in the context of gemtuzumab ozogamicin treatment: Results of the ALFA-0701 trial. Oncotarget. 2014;5(4):916.##Gamis AS, Alonzo TA, Meshinchi S, Sung L, Gerbing RB, Raimondi SC, et al. Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children's Oncology Group trial AAML0531. Journal of Clinical Oncology. 2014;32(27):3021-32.##Daver NG, Montesinos P, DeAngelo DJ, Wang ES, Papadantonakis N, Deconinck E, et al. Clinical profile of IMGN632, a novel CD123-targeting antibody-drug conjugate (ADC), in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) or blastic plasmacytoid dendritic cell neoplasm (BPDCN). Blood. 2019;134:734.##https://doi.org/10.1182/blood-2019-128275##Bakker ABH, van den Oudenrijn S, Bakker AQ, Feller N, van Meijer M, Bia JA, et al. C-type lectin-like molecule-1: a novel myeloid cell surface marker associated with acute myeloid leukemia. Cancer Res. 2004;64(22):8443-50.##Van Rhenen A, Van Dongen GAMS, Kelder A, Rombouts EJ, Feller N, Moshaver B, et al. The novel AML stem cell-associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells. Blood, The Journal of the American Society of Hematology. 2007;110(7):2659-66.##Jiang YP, Liu BY, Zheng Q, Panuganti S, Chen R, Zhu J, et al. CLT030, a leukemic stem cell-targeting CLL1 antibody-drug conjugate for treatment of acute myeloid leukemia. Blood Adv. 2018;2(14):1738-49.##Uy GL, Godwin J, Rettig MP, Vey N, Foster M, Arellano ML, et al. Preliminary results of a phase 1 study of flotetuzumab, a CD123 x CD3 bispecific Dart® protein, in patients with relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome. Blood. 2017;130:637.##Leong SR, Sukumaran S, Hristopoulos M, Totpal K, Stainton S, Lu E, et al. An anti-CD3/anti-CLL-1 bispecific antibody for the treatment of acute myeloid leukemia. Blood, The Journal of the American Society of Hematology. 2017;129(5):609-18.##Lee EM, Yee D, Busfield SJ, McManus JF, Cummings N, Vairo G, et al. Efficacy of an Fc-modified anti-CD123 antibody (CSL362) combined with chemotherapy in xenograft models of acute myelogenous leukemia in immunodeficient mice. Haematologica. 2015;100(7):914.##Kubasch AS, Platzbecker U. Beyond the edge of hypomethylating agents: novel combination strategies for older adults with advanced MDS and AML. Cancers (Basel). 2018;10(6):158.##Vallera DA, Felices M, McElmurry R, McCullar V, Zhou X, Schmohl JU, et al. IL15 trispecific killer engagers (TriKE) make natural killer cells specific to CD33+ targets while also inducing persistence, in vivo expansion, and enhanced function. Clinical Cancer Research. 2016;22(14):3440-50.##Raneros AB, Puras AM, Rodriguez RM, Colado E, Bernal T, Anguita E, et al. Increasing TIMP3 expression by hypomethylating agents diminishes soluble MICA, MICB and ULBP2 shedding in acute myeloid leukemia, facilitating NK cell-mediated immune recognition. Oncotarget. 2017;8(19):31959.##Schmohl JU, Felices M, Todhunter D, Taras E, Miller JS, Vallera DA. Tetraspecific scFv construct provides NK cell mediated ADCC and self-sustaining stimuli via insertion of IL-15 as a cross-linker. Oncotarget. 2016;7(45):73830.##Ojo EO, Sharma AA, Liu R, Moreton S, Checkley-Luttge MA, Gupta K, et al. Membrane bound IL-21 based NK cell feeder cells drive robust expansion and metabolic activation of NK cells. Sci Rep. 2019##9 (1): 14916. Epub 2019/10/19. doi: 10.1038/s41598-019-51287-6. PubMed PMID: 31624330;##Leong JW, Chase JM, Romee R, Schneider SE, Sullivan RP, Cooper MA, et al. Preactivation with IL-12, IL-15, and IL-18 induces CD25 and a functional high-affinity IL-2 receptor on human cytokine-induced memory-like natural killer cells. Biology of Blood and Marrow Transplantation. 2014;20(4):463-73.##Buyse M, Squifflet P, Lange BJ, Alonzo TA, Larson RA, Kolitz JE, et al. Individual patient data meta-analysis of randomized trials evaluating IL-2 monotherapy as remission maintenance therapy in acute myeloid leukemia. Blood, The Journal of the American Society of Hematology. 2011;117(26):7007-13.##Mao C, Fu X, Yuan J, Yang Z, Huang Y, YE Q, et al. Interleukin‐2 as maintenance therapy for children and adults with acute myeloid leukaemia in first complete remission. Cochrane Database of Systematic Reviews. 2015;(11).##Cooley S, He F, Bachanova V, Vercellotti GM, DeFor TE, Curtsinger JM, et al. First-in-human trial of rhIL-15 and haploidentical natural killer cell therapy for advanced acute myeloid leukemia. Blood Adv. 2019;3(13):1970-80.##Soiffer RJ. Can IL-15 superagonist ALTer GVL? Blood, The Journal of the American Society of Hematology. 2018;131(23):2511-2.##Vasu S, Sharma N, Odonnell L, Bosse K, Lee DA. A phase I clinical trial testing the safety of IL-21-expanded, off-the-shelf, natural killer cells for relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome. American Society of Clinical Oncology; 2020.##Smits ELJM, Anguille S, Berneman ZN. Interferon α may be back on track to treat acute myeloid leukemia. Oncoimmunology. 2013;2(4):e23619.##Sobash PT, Kolhe R, Karim NA, Guddati AK, Jillella A, Kota V. Role of indoleamine 2, 3-dioxygenase in acute myeloid leukemia. Future Oncology. 2020;16(36):3085-94.##Joshi M, Pathak S, Sharma S, Patravale V. Design and in vivo pharmacodynamic evaluation of nanostructured lipid carriers for parenteral delivery of artemether: Nanoject. Int J Pharm. 2008;364(1):119-26.##Otegbeye F, Ojo E, Moreton S, Mackowski N, Lee DA, De Lima M, et al. Inhibiting TGF-beta signaling preserves the function of highly activated, in vitro expanded natural killer cells in AML and colon cancer models. PLoS One. 2018;13(1):e0191358.##Oka Y, Tsuboi A, Taguchi T, Osaki T, Kyo T, Nakajima H, et al. Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proceedings of the National Academy of Sciences. 2004;101(38):13885-90.##Maeda T, Hosen N, Fukushima K, Tsuboi A, Morimoto S, Matsui T, et al. Maintenance of complete remission after allogeneic stem cell transplantation in leukemia patients treated with Wilms tumor 1 peptide vaccine. Blood Cancer J. 2013;3(8):e130-e130.##Maslak PG, Dao T, Bernal Y, Chanel SM, Zhang R, Frattini M, et al. Phase 2 trial of a multivalent WT1 peptide vaccine (galinpepimut-S) in acute myeloid leukemia. Blood Adv. 2018;2(3):224-34.##Anguille S, Van de Velde AL, Smits EL, Van Tendeloo VF, Juliusson G, Cools N, et al. Dendritic cell vaccination as postremission treatment to prevent or delay relapse in acute myeloid leukemia. Blood, The Journal of the American Society of Hematology. 2017;130(15):1713-21.##Khoury HJ, Collins Jr RH, Blum W, Stiff PS, Elias L, Lebkowski JS, et al. Immune responses and long‐term disease recurrence status after telomerase‐based dendritic cell immunotherapy in patients with acute myeloid leukemia. Cancer. 2017;123(16):3061-72.##Rosenblatt J, Stone RM, Uhl L, Neuberg D, Joyce R, Levine JD, et al. Individualized vaccination of AML patients in remission is associated with induction of antileukemia immunity and prolonged remissions. Sci Transl Med. 2016;8(368):368ra171-368ra171.##Shah NJ, Najibi AJ, Shih TY, Mao AS, Sharda A, Scadden DT, et al. A biomaterial-based vaccine eliciting durable tumour-specific responses against acute myeloid leukaemia. Nat Biomed Eng. 2020;4(1):40-51.## ##

Efficacy and Challenges of Pediatric Cord Blood Transplantation: Insights from a Retrospective Single-Center Study 2 2 Background: Umbilical cord blood transplantation (UCBT) serves as a valuable alternative for pediatric patients without matched donors, particularly in urgent situations where timely transplantation is critical. While UCBT offers immunological benefits and broader donor availability, its clinical outcomes remain inconsistent, especially in non-malignant hematologic disorders. Objective: To evaluate clinical outcomes of UCBT in pediatric patients with malignant and non-malignant hematologic conditions, focusing on transplant-related complications and survival rates. Methods: In this retrospective single-center study, we analyzed 14 pediatric patients (aged 0.7–11 years) who underwent allogeneic UCBT at Mofid Children’s Hospital between 2019 and 2024. Data were extracted from institutional registries and medical records, including patient demographics, disease classification, graft characteristics, conditioning regimens, engraftment status, incidence of graft-versus-host disease (GVHD), infections, and survival outcomes. Results: Among the 14 patients, 85.7% had non-malignant disorders. Most received unrelated donor grafts, with HLA matching of 6/6 in 42.9%, 5/6 in 50%, and 4/6 in 7.1%. The median total nucleated cell dose was 4.95×10⁷/kg, and the median CD34⁺ cell dose was 1.7×10⁵/kg. Neutrophil engraftment was achieved in 42.9% of patients, with a median of 19 days. Primary graft failure occurred in 50% of patients, and secondary graft failure in 7.1%. Acute GVHD developed in 14.3% of cases, while no chronic GVHD was observed. CMV reactivation occurred in 42.9% of patients, and bacterial infections were reported in 57.1%. The overall survival rate was 42.9%, with transplant-related mortality accounting for 57.1% of cases, due to infections and graft failure. Conclusion: UCBT remains a feasible therapeutic option for pediatric patients lacking matched donors, particularly in urgent or resource-constrained settings. However, the high incidence of graft failure and infection-related mortality highlights the need for improved graft selection strategies, personalized conditioning protocols, and optimized post-transplant care to enhance patient outcomes. 96 105 2025/07/42025/07/142025/08/192025/07/242025/07/172025/08/102025/07/102025/08/112025/07/212025/10/28 1404/8/6 2025/09/242025/09/112025/09/112025/09/112025/09/172025/09/252025/09/102025/09/252025/09/112025/11/15 1404/8/24 Bibi Shahin Shamsian Bibi Shahin Shamsian Pediatric Congenital Hematologic Disorders Research Center, Research Institute for Children’s Health, Shahid Beheshti University of Medical Sciences, Tehran, Iran Nader Momtazmanesh Nader Momtazmanesh Pediatric Congenital Hematologic Disorders Research Center, Research Institute for Children’s Health, Shahid Beheshti University of Medical Sciences, Tehran, Iran Vahide Zeinali Vahide Zeinali Research Institute for Children’s Health, Shahid Beheshti University of Medical Sciences, Tehran, Iran Arezou Sayad Arezou Sayad Genomic Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran sharareh kamfar sharareh kamfar Pediatric Congenital Hematologic Disorders Research Center, Research Institute for Children’s Health, Shahid Beheshti University of Medical Sciences, Tehran, Iran. kamfarsharareh@gmail.com Umbilical cord blood transplantation Graft-versus-host disease HLA matching Neutrophil engraftment Graft failure ## ##